University of Wollongong

Research Online
Faculty of Science, Medicine and Health Papers: part A

Faculty of Science, Medicine and Health

1-1-2015

Points to consider in the development of seed stocks of pluripotent stem
cells for clinical applications: International Stem Cell Banking Initiative
(ISCBI)
Peter W. Andrews
University of Sheffield

Duncan Baker
Sheffield Children's NHS Foundation Trust

N Benvinisty
Hebrew University of Jerusalem

B Miranda
Biobank Andalousian Public Health System

K Bruce
Roslin Cells Ltd.

See next page for additional authors
Follow this and additional works at: https://ro.uow.edu.au/smhpapers
Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences
Commons

Recommended Citation
Andrews, Peter W.; Baker, Duncan; Benvinisty, N; Miranda, B; Bruce, K; Brustle, O; Choi, M; Choi, Young Min;
Crook, Jeremy M.; and de Sousa, Paul A., "Points to consider in the development of seed stocks of
pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)" (2015).
Faculty of Science, Medicine and Health - Papers: part A. 3186.
https://ro.uow.edu.au/smhpapers/3186

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Points to consider in the development of seed stocks of pluripotent stem cells
for clinical applications: International Stem Cell Banking Initiative (ISCBI)
Abstract
In 2009 the International Stem Cell Banking Initiative (ISCBI) contributors and the Ethics Working Party of
the International Stem Cell Forum published a consensus on principles of best practice for the
procurement, cell banking, testing and distribution of human embryonic stem cell (hESC) lines for
research purposes [1], which was broadly also applicable to human induced pluripotent stem cell (hiPSC)
lines. Here, we revisit this guidance to consider what the requirements would be for delivery of the early
seed stocks of stem cell lines intended for clinical applications.
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Points to consider in the development of seed
stocks of pluripotent stem cells for clinical
applications: International Stem Cell Banking
Initiative (ISCBI)
1. Background and utility of this
document
In 2009 the International Stem Cell Banking
Initiative (ISCBI) contributors and the Ethics
Working Party of the International Stem Cell
Forum published a consensus on principles of
best practice for the procurement, cell banking,
testing and distribution of human embryonic
stem cell (hESC) lines for research purposes [1],
which was broadly also applicable to human
induced pluripotent stem cell (hiPSC) lines.
Here, we revisit this guidance to consider what
the requirements would be for delivery of the
early seed stocks of stem cell lines intended for
clinical applications. The term ‘seed stock’ is
used here to describe those cryopreserved stocks
of cells established early in the passage history
of a pluripotent stem cell line in the lab that
derived the line or a stem cell bank, hereafter
called the ‘repository’. The seed stocks should
provide cells with suitable documentation and
provenance that would enable them to be taken
forward for development in human therapeutic
applications. WHO recommendations for the
evaluation of animal cell cultures as substrates
for the manufacture of biologicals and for the
characterization of cell banks were updated in
2010 and provide a number of definitions and
guiding principles that may apply to stem cells.
The term ‘cell bank’ is used to describe a stock of
vials or other containers of cells with consistent
composition aliquoted from a single pool of cells
of the same culture history (for other specific
definitions see PAS 84 [2] and WHO [3]).
Three important assumptions have been made
in the preparation of this document. First, that
seed stocks of hPSCs are used as starting materials to make cell banks for use in clinical trials. The cell banks made within a clinical trial
would need to be established according to Good
Manufacturing Practice (GMP) in a facility with
a relevant product manufacturing license. These
banks would need additional risk assessment
focused on the new banking process/reagents
and the specific intended clinical application.
10.2217/RME.14.93 © 2015 Future Medicine Ltd

Second, it has been assumed that undifferentiated pluripotent stem cells would not be inoculated into patients. Third, where feeder cells are
used to culture hPSC lines, their cellular nature
and intimate contact with the therapeutic cells
means that they should be subject to similar risk
assessment and banking procedures as applied to
the hPSC cells.
It is important to note that responsibility
for establishing and updating national regulations for medicinal products relies on National
Regulatory Authorities. Therefore, national
requirements for cell therapy may vary considerably. Accordingly, it is not intended that this
international consensus provides comprehensive guidance that will ensure compliance with
requirements in any given jurisdiction. Rather,
it is designed to aid the development of clinical
grade materials by providing points to consider
in the preparation of seed stocks of stem cell lines
for use in cell therapy. It may arise that there are
circumstances where it is not reasonably possible to meet specific procedures presented in this
document. Where this is the case any alternative procedures should be justified and mitigate
against any adverse consequences. Finally, this
document could also serve as a useful reference
to assist in the evaluation of potential sources
of candidate cell lines for the development of
cell-based medicines, and provide the links necessary to identify some of the key differences in
regulatory requirements between countries.
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2. Governance and ethics

2.1 General principles
Centers banking stem cell lines (hereafter called
repositories) should adopt transparent and
harmonized protocols for the collection, storage, access, and use of the cell lines that they
curate. As part of a comprehensive governance
structure, repositories should establish robust
mechanisms for the authentication of bone fide
users and should strive for equitable and transparent conditions of access and of material transfer (Appendices 1a, 1b and 2). Such protocols
Regen. Med. (2015) 10(2)s, 1–44
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should be adopted according to internationally
accepted principles for research ethics and in
compliance with applicable legal, ethical and
regulatory requirements (Appendix 3, 4 and
5). Furthermore, repositories should establish
a system for documenting and monitoring performance with respect to such principles and
requirements.

2.2 Key issues in determining
provenance of pluripotent stem cell
lines
Repositories should ascertain the provenance
(source/origin) of the human biological specimens from which the pluripotent stem cell lines
have been derived. International guidance exists
for documenting the provenance of the cell lines
[1,4–7].
Important issues to consider when evaluating
provenance include:

Evidence of free and voluntary informed consent, for the proposed research use, in conjunction with independent review and oversight, with particular attention given to disclosure of potential clinical and commercial
applications.

The extent to which reimbursement (e.g.,
expenses, financial incentives, monetary payments) were provided for donation of biological samples.

The ability of the donor to withdraw original
specimens, derived cell lines, data or otherwise
to discontinue participation in research.

The possibility that derived cell lines may be
used for a wide range of research, possibly
through a public repository.

The establishment of robust systems for data
security and traceability.

The implementation of mechanisms for the
protection of donor privacy and confidentiality. Particular attention should be given to the
generation and use of genome sequence data.
Many national and more local jurisdictions
have explicit policies governing the acquisition
and use of human biospecimens for pluripotent
stem cell derivation, particularly with regard to
embryonic sources (Appendix 3 and 4). Prior to
accepting a pluripotent stem cell line, a repository should determine its provenance by first
documenting that the biospecimen was collected
and the cell line derived in a manner broadly
consistent with international standards for
2
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research ethics [4,5,6,7,201]; and second, to make a
positive determination that the biospecimen was
obtained in a manner consistent with applicable
laws in the country of origin.
2.2.1 Provenance determination and
international standards

Providers of cells should be able to demonstrate
to the repository that they have met all applicable
legal and ethical requirements associated with
the procurement of a human biospecimen from
which a pluripotent stem cell line was derived.
Given the heterogeneity of national laws and
regulations governing research and clinical
applications, the depositor of a cell line should
provide information that enables the repository
governance structure to determine whether the
conditions of derivation, use and distribution are
broadly consistent with the repository’s national
regulation. Moreover, repositories should have
in place a mechanism (e.g., ‘horizon scanning’,
advisory board) to track changes in the legal
and regulatory frameworks. In addition, repositories should verify and retain sufficient documentation to support a determination that each
cell line has been obtained in accordance with
international standards for research ethics.
Key principles include the following:
Independent review and oversight

The protocol for procurement of tissues, gametes
or embryos for the purpose of generating a pluripotent stem cell line should be subject to independent scientific and ethical review. Review
bodies include ethics committees, licensing
bodies or committees responsible for oversight
of research involving human subjects.
Voluntary informed consent

In addition to verifying appropriate informed
consent, the repository should ascertain additional details regarding donor’s disclosure
when available (Appendix 1b). Numerous bodies and national policies recommend or require
the disclosure of specific information to donors
(particularly for hESC derivation). A number
of jurisdictions have consent requirements that
include, but are not limited to, disclosure of possible human transplantation, genetic modification,
international sharing and commercial potential.
Documentation of a robust informed consent process that addresses these requirements can serve
to support wide distribution and utilization of the
cell lines (Appendix 3 and 4). Informed consent
requirements for stem cell derivation, use and
banking have evolved over time and jurisdictional
future science group
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variations may exist for different sources of biospecimens. In addition, standards for evaluating
informed consent processes may need to be flexible and allow for context-specific considerations.
For example, agreement to banking could include
broad consent to future unspecified research
(subject to appropriate security mechanisms
and governance); whereas some protocols may
be intended to develop a specific cell product.
Donors should be notified of the possibility of
future use in cellular therapies, commercialization
of eventual products and of the international sharing of samples and of stem cell lines. Moreover,
donors should also be informed of the limitations
in privacy protection (see section 3.2 & 5.1) given
the need to assure traceability for safety reasons
(see section 6.9).
Gratuitous donation

Donors should not be paid to provide somatic
cells, gametes or embryos for stem cell derivation,
nor should they be reimbursed for any costs, such
as tissue storage, prior to the decision to donate.
2.2.2 Compliance determination and
access policies

Mechanisms should be in place to make a positive determination of compliance with both
the ethical and legal requirements of the jurisdiction of biospecimen’s origin, together with
those of the jurisdiction where the cell line was
derived, deposited, and will be used in research
(Appendix 3 and 4). Furthermore, it is important to consider that there may be jurisdictional
or funding agency restrictions on the types of
cell lines eligible for research use as may be the
case for hESC lines. To the extent feasible the
repository should strive to compile complete
provenance information for evaluation; however,
it is ultimately incumbent on the end user of the
cell line to determine that its provenance meets
local ethics and legal requirements.
Repositories should also adopt transparent,
flexible and equitable access policies. Given the
importance of international collaboration, such
policies should include procedures for deposit of
cell lines of foreign origin, and for the distribution of cell lines to researchers in other jurisdictions. Among the policy criteria to be considered
are the following:

Mutual recognition via ‘reciprocal policy
agreements’ allowing for transnational sharing
of cell lines provided that the cell lines were
derived by, or approved for use by, a licensing
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entity formally recognized as having adopted
consistent ethical and legal requirements.

‘Substantial equivalency’ whereby criteria for
cell line derivation, use, and banking in different jurisdictions involve ethical and legal
requirements that are deemed to be ‘broadly’
or ‘substantially’ acceptable to the repository
management and under applicable regulation.

3. Provenance and selection of donor
tissue

3.1 Donor selection, screening and
medical records
Eligibility criteria for embryo, cell or tissue
donors intended for human transplantation are
subject to national regulatory frameworks and
institutional protocols in the jurisdiction of origin. As a general rule, donor eligibility determination requires screening for risk factors associated with infection and communicable disease.
These are typically focused on serum human
viral blood-born pathogens (e.g., HIV, hepatitis
B virus, hepatitis C virus) and may also include
other pathogens endemic to the donor’s origin
(e.g., human T-cell lymphotropic virus I&II,
Chaga’s disease, malaria). Donor testing for
these agents may be required to be carried out
under national licensed facilities.
For hESCs there are a number of considerations pertaining to donor screening protocols
for assisted reproduction treatment (Appendix
4). For hiPSC evaluation, inclusion and exclusion criteria represent a starting point for riskassessment or risk mitigation. In some cases,
inclusion criteria may call for the collection
of cells and tissues from patient groups with
specific clinical (disease) indications. Any
information regarding known disease indication should be associated with specific cell
and tissue samples to support risk evaluation
(see section 6.3). While cell lines derived from
patients with inherited disease have been recognized as having potential scientific utility, they
are unlikely to be suitable for development of
general clinical applications.
Finally, regulatory authorities responsible
for the evaluation of biological products consistently emphasise the value of a donor medical history. It is important to note that rules
adopted in some jurisdictions may require a
review of donors’ relevant medical records
and or a medical history screening; considerations for extended medical histories have been
published by Murdoch et al. [8].

www.futuremedicine.com
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3.2 Allogeneic cell transplantation
The establishment of hiPSC repositories for
human leukocyte antigen (HLA) haplotype representation to facilitate immune-genetic matching is a proposition already being pursued. Of
particular interest are individuals who will be
homozygous for common HLA haplotypes to
maximise prospective histocompatibility matching, although it is important to note that rejection will also be mediated by other non-HLA
associated molecules. In the establishment of
these resources, health screening, medical history and life style documentation will be important sources of information the help assure the
prospective patient safety as described below.
However, defining what constitutes a a fully
functional and ‘safe’ genetic state is more problematic and may not be resolved by development
of autologous hiPSC lines as observed in mouse
models. For hESCs derived from surplus IVF
embryos, the risk of carrying genetic deficiencies has largely been presumed minimal. This is
based on two presumptions: that the infertility
of the donors is not in fact a congenital deficiency, and that the culture and manipulation
of embryos in vitro does not result in genetic
and epigenetic perturbations. For hPSC lines
in general, it is not possible to screen for cell
inheritable genetic or epigenetic conditions that
are not known, and these risks are thus tolerated
(Advisory Committee on the Safety of Blood,
Tissues and Organs [SaBTO] [9]). In the case
of some homozygous HLA haplotypes there are
also disease associations (see section 4.4).
There is a reasonable prospect that in the near
future there will be affordable access to personalized genomic sequence information. If genomic
sequence information of banked hiPSC lines
were also made openly available to research, then
anonymized, or de-identified, donors could ultimately identify cell lines derived from them, or
conversely be potentially identified by others [10].
Banking of hiPSC lines may, therefore, require
greater attention to systems for preserving donor
privacy [11].

3.3 Ongoing donor traceability and
management of post-donation disease
and adverse events in patient
treatment
Ideally, there should be a mechanism that allows
a link to be made between cell line and donors,
but only in exceptional circumstances such as
seeking reconsent or to facilitate reporting of
serious post-donation disease e.g., hepatitis C
virus, variant Creutzfelt–Jakob Disease (CJD).
4

Regen. Med. (2015) 10(2)s

While this should be considered, a risk–benefit
analysis should also be carried out taking into
account the administrative costs, together with
ethical and policy considerations that such a
system could impose. Of course, the repository
should ensure that there is an effective tracking
system for the cellular materials, from reception
of tissue to the point of release to users to support
internal troubleshooting and to enable management of adverse events in clinical trials (section
6.9). To this end, the donor’s informed consent
should ideally allow for linkage to medical history and permission to re-contact. Linkage and
re-contact will also raise, however, the possibility of donor(s) withdrawal (see section 2 and
Appendices 3 & 4).
In cases where the institution that creates the
seed stock is a separate entity from the procurement institution, the repository should retain
sufficient records to allow traceability to the
initial sample, while detailed information relating to procurement process and donor identity
may remain with the organisation responsible
for procurement (see section 6.8).

3.4 Advantageous capture of
biological specimens
In certain jurisdictions it is required that donor
blood samples be associated with embryos
intended for assisted reproductive treatments.
Consequently, there may be blood or other biological specimens associated with some banked
embryos and similar arrangements may be in
place for some hiPSC lines. While such samples
could inform future investigations, they are
unlikely to have been consented for this purpose
and retention of blood samples from embryo
donors may not be the best archive material to
use for the purpose of microbial safety testing. In
fact samples from the cell line seed stock may be
more appropriate for this purpose as proposed by
Murdoch et al. [8]. For discussion on the consent
issues relating to the use of archive tissues for the
generation of hiPSC lines see Lomax et al. [12].

3.5 Donor medical histories
In a number of jurisdictions a donor medical
history may be required that identifies potential
hazards in the past of the donor or their family
and may also relate to aspects of the donor’s lifestyle that may be associated with risk of infection. Repositories may wish to assure themselves
that such information is accessible and even collate it in an anonymized, or de-identified, form
(i.e., with donor name redacted); however, this
may not be possible in some jurisdictions.
future science group
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If medical histories are not collected at the time
of donation, re-contacting donors may be difficult
or impossible if, for instance, they have changed
location or have become deceased. When establishing requirements for collecting donor medical
histories, it is important to decide what information will be useful to collect [8].This will include
risk factors such as sexual activity, drug abuse,
cancer and family history of hereditary disease
such as familial CJD. Finally, it is important to
recognise that the management of donors may
vary considerably in different jurisdictions, and
in addition, the veracity of information provided
by donors on certain risk factors may be difficult
to determine. In conclusion, medical histories,
in combination with donor virological testing,
can be useful to screen out donated tissues carrying higher risk of transmitting certain infections
or other disorders, and thereby mitigate against
certain risk factors. However, these alone do not
necessarily assure safety of cell lines selected for
use in clinical products, which will require supplementary risk assessment and testing, as described
in sections 4 and 5.

3.6 Disclosure of significant clinical
information
In carrying out hPSC research, increasingly large
genetic data sets are being generated. These will
inevitably contain information on infectious
disease and genetic inherited disorders that
may be of relevance to the health of the donor
and/or their relatives. The return of individual
research results and incidental findings should
be warranted and supported by informed donor
consent, but also by protocols comprehensively
detailing the nature of such findings, the mechanisms for disclosure and their management.
Ideally, these procedures should be established
prior to obtaining informed consent to donate.
Moreover, such protocols should be transparent
with regard to the conditions for such contextspecific and qualified disclosure [5].

3.7 Withdrawal of bio-specimens
and/or associated data
Obtaining medical information or other donor
information on an ongoing basis constitutes
human subjects research, and therefore, the participant has the right to discontinue participation
(research withdraw). The extent to which a participant may withdraw will vary depending on
the research protocol and applicable laws, but the
withdrawal policy should be clearly described in
the informed consent document. The following
are common examples of withdrawal policies:
future science group
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Donors may request that donated embryos for
hESC derivation, or somatic cells for hiPSC
derivation, may be destroyed. However, it is
generally accepted that derived hESC or
hiPSC lines may continue to be used, and distributed materials cannot be recalled.

Donors may request that all individually identifying information be removed from donated
samples or resulting cell lines.

Donors may request that further collection of
medical information cease. Policies and legislation vary with regard to the status of medical
information already associated with a cell line.

Donors may request to withdraw consent up to
the time their tissue is used to derive a cell line.

Donors may request that they are no longer to
be contacted by researchers.
Any or all of the above provisions may be
applicable to a particular hESC or hiPSC line.
Typically, donors are offered ‘staged’ withdrawal
options where they may apply one or more of the
options above, possibly at different time periods. It is important that the investigator or party
responsible for interacting with the donor and
the repository have clear procedures and protocols in place to act upon withdrawal requests in
a timely and effective manner.

4. Safety assessment of hPSC seed
stocks
Whilst microbiological contamination is the most
immediately evident hazard from cells intended
for human therapy, there are a number of additional factors that should be considered. These
include the presence of transformed cells, expression of potentially damaging bioactive molecules
and the appearance of novel surface molecules
following in vitro isolation and culture. The presence of potentially tumorigenic cells is clearly
undesirable in a cell culture intended for clinical
application. However, the remaining non-microbiological factors are more difficult to evaluate in
terms of safety and more experience in the use
of hPSC lines will be needed to assess the exact
nature of any risk to patients. This section considers the primary biological issues for hPSC lines
that will have a critical impact on their safe use
in cell-based medicines, and considers approaches
to reduce the risk of these hazards employing a
risk-based approach.
It is obviously desirable that each stem cell
line established for clinical use should be available for use in a broad range of therapies. The
specific clinical settings and therapies to be
www.futuremedicine.com
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developed from these seed stocks are unlikely
to be known and it is therefore not possible
to carry out a full risk analysis that would be
needed to determine the testing regime for a
cell line used for a wide range of therapies. The
testing regime required for release of cell banks
will, therefore, inevitably be based on the likely
generic hazards associated with cell culture and
the specific hazards associated with the origin
and specific culture history of each cell line on
a case by case basis (see sections 4 & 6). All
testing used for release of clinical grade seed
stocks should be performed by a qualified and
accredited laboratory according to national
and/or international regulation and guidance.
Similar standards should be applied to any cell
banks of partially differentiated or feeder cells.
It is recommended for a manufacturer using
a cell line to produce a cell-derived biological
product to focus testing and characterization on
vials from the master cell bank (MCB) [3]. This
practice can make testing regimes more efficient
and ensures the MCB is fit, according to current
best practice, for production of future working
cell banks (WCBs). Additional testing of WCBs
should be considered where justified based on
science-based risk assessment, such as the risk
of an expansion of a viral contaminant from
culture reagents or a clonal expansion of karyologically abnormal cells. However, developing
guidance [3,14] proposes that alternative strategies
may be justified, such as exhaustive testing of
each working cell bank as it is produced.

4.1 Microbiological hazards
4.1.1 General considerations on
microbiological hazards

A very broad range of microorganisms could
potentially contaminate hPSC lines and some
may be able to grow in cell culture becoming a
permanent and non-cytopathic component of the
cell culture. In addition, some of these organisms
may have the capacity to transform human cells
and present a tumorigenic hazard for clinical use
[9]. The primary risk of contamination arises from
the donor tissue used to generate the cell line and
the associated most likely contaminants will, to
some degree, be different for hPSC lines derived
from embryos, where contamination from the
reproductive tract may need to be considered,
compared to hiPSC lines isolated from blood
or skin cells. In addition, donor history (section
2) and history of the cell line including storage
conditions and detailed records of the reagents
used (section ), provide the key information to
assess risk of contamination for each hPSC line.
6
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This risk assessment can then be used to establish the testing regime for the seed stocks of each
cell line. Whilst virological testing of a donor is
useful information in risk assessment, it does not
guarantee freedom from viral contamination of a
cell line derived from that donor’s tissue. Thus, in
addition to risk mitigation (see section 6.2 & 6.3),
microbiological testing of a cell line will provide
confidence in its safety for use in humans.
When cells are transferred from supplier to
the manufacturer, a different set of conditions
and reagents will apply and the appropriate testing regime for MCBs and WCBs established for
generating the cell therapy product, will need
to be reassessed. Moreover, regulators are likely
to expect fully qualified cell banks for manufacturing purposes, as recommended for banks
of cells used in other aspects of manufacturing
[3,13]. With this in mind some stem cell line
repositories may choose to perform testing on
seed stock cell banks only for the most serious
potential contaminants, whilst others may carry
out a borader range of testing on their cells.
Highly sensitive molecular and cell culture
based assays have been established and qualified
for the evaluation of cells used in the manufacture
of vaccines and biotherapeutics [3,13]. However,
it is important to recognise that current qualified methods are not sufficiently broad ranging
to provide an absolute guarantee of absence of
microbial contamination. Deep sequencing technologies and microarray technologies [14–16] offer
significant potential advances in the detection of
virtually any agent in cell cultures, as has been
demonstrated in cells used for vaccine manufacture [17,18]. However, they have yet to be proven
and validated for use with cell banks for clinical
use. Repositories should keep a ‘watching brief’
on emerging technologies and engage with their
developer to assemble and analyze data that may
be useful for clinical validation. Currently, such
novel techniques lack appropriate validation for
detection of different types of agents. It will be
necessary to have widely available control materials and procedures to manage unqualified data as
developed by WHO for sequencing [19], and by
the Minimum Information About a Microarray
Experiment (MAIME) workgroup [20]) to provide
minimal datasets from microarrays for interpreting and assessing reproducibility of experiments.
4.1.2 Microbiological testing

The following sections discuss the typical microbiological tests that should be considered for seed
stocks of hPSC lines intended for clinical use
and an example of a possible core testing regime
future science group
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for a seed stock of hPSC is provided in Appendix
6 (of note, this is a guide only to key issues and
each repository must take responsibility for risk
assessment and the final testing regime). ‘Next
Generation Sequencing’ (NGS) offers powerful methodologies for the identification of any
contaminant including organisms unknown to
science. However, care is required in interpreting data as widely available control materials
and qualification data are yet to be established.
Accordingly, the real value of a negative or a
positive result may be uncertain. However, it has
proved useful to pick up positive signals which
must be verified by standardized and established
techniques.
Virological testing

Current established testing regimes do not
enable routine release assays for detection of
all known viral agents, and a risk assessment
should be performed to ensure that tests for the
most likely contaminants are applied based on
risk associated with the origin and culture history of the cell line (see section 6.8). As already
described, the more complete the documentation
for the culture history of the hPSC line, the more
robust the risk assessment can be and this in turn
reduces the dependency on the cell bank safety
testing regime.
The risk of contamination of cell therapies
by abnormal prion protein can be mitigated by:

Ensuring that any potentially contaminated
culture reagents are traceable to low risk
source materials.

Sequencing of the associated prion gene to
identify any cell types with mutations more
susceptible to conversion to the abnormal
state.

Testing regimes for particular abnormal proteins of concern.

Demonstrating failure of prion agents to survive and multiply in cell lines selected for
development of cell therapies.
The WHO has published suitable risk assessment procedures to enable selection of source
tissue of low risk [21], and this has been reflected
in European guidance [22,23].
Repositories should ensure they have access
to expert microbiological advice, usually in the
form of an expert advisory group, which provides
assistance in establishing local testing regimes.
It is also beneficial for repositories to coordinate
such activities to enable them to keep abreast
of developments in emerging diseases and
future science group
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experience with contamination. It is important
for banks to evaluate the risks associated with
reagents (e.g., growth factors; see section 6.3)
and ensure the appropriate sourcing of components of lowest microbiological risk – especially
for reagents such as serum and trypsin, where
the reagent cannot be sterilized.
Sterility testing

Standard methods for sterility testing are published by national authorities including the United
States Pharmacopeia (USP), and the European
Pharmacopeia (EP). Each repository should
comply with its own national pharmacopoeia.
However, these protocols are aimed to detect
breaches in aseptic processing and typically do
not use culture conditions that would enable isolation of some more fastidious organisms that could
proliferate in the complex media and conditions
of cell culture. Additional detection methods may
need to be considered to detect such organisms
where they are considered to be a special hazard
in the local environment or particular reagents. It
is important to emphasise that antibiotics should
not be used in culture media before sterility or
mycoplasma testing is performed. In addition,
antibiotics and antifungal agents should not be
used in preparation of cells intended for therapy.
Mycoplasma testing

Standard methods based on Vero cell inoculation/DNA stain and culture isolation methods
are published in USP, EP and other pharmacopeia. Polymerase chain reaction (PCR) methods are published and certain assay systems are
accepted by the European Pharmacopeia but are
not necessarily represented in all national pharmacopeia [24,25].
Nested PCR may give greater sensitivity of
detection, however, it can also give rise to false
negatives. Direct quantitative PCR (qPCR)
applied to inoculated mycoplasma broths may
provide significant advantages regarding sensitivity. Whichever method is selected, as for all
analytical methods it will need to be qualified,
and in routine testing working reference materials should be established (e.g. DNA preparations, quantified suspensions of organisms) to
monitor sensitivity of testing over time.

Genetic stability
4.2.1 General considerations on genetic
stability

Genetic changes that are known to occur in
cultured hPSC lines [26– 28] could have a number of deleterious effects including loss of
www.futuremedicine.com
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functional characteristics and transformation
into a tumorigenic state [29,30]. Cell lines in culture are known to be karyologically variable,
and even human diploid fibroblasts, noted for
their karyological stability, show subtle mutations when analysed by single nucleotide polymorphism (SNP) arrays [31–36]. Non-diploid
karyotypes are sometimes seen in apparently
‘normal’ tissues. While the significance of such
karyologically abnormal cells in vitro is yet to
be determined they are considered a potentially
serious issue for cells intended for implantation
into humans. SNP variation in non-pluripotent cells such as fibroblasts, mentioned above,
could identify a baseline for genetic stability,
but such base-lines may well vary with cell type
and culture conditions.
The degree of genetic stability of cultured
cell lines intended for cell therapy should be
a consideration in their selection, however, as
already indicated, no cell line is likely to be
absolutely stable in its genetic make-up when
passaged in vitro. Risk associated with genetic
instability can be minimized by limiting the
time and number of passages in vitro (of note,
cumulative population doublings should be used
if these can be determined), and risk assessments
should include consideration of the influence of
any changes or variation in culture conditions.
It has been clearly demonstrated that genetic
changes occur in the early phase of hiPSC line
derivation [37,38] and such changes may give a
selective advantage for in vitro culture [39,40].
Selection of methods of hPSC line isolation that
minimize the risk of such changes should be a
significant consideration in cell line development and selection of hPSC lines to be banked
for clinical application.
There is also evidence that culture conditions
and passaging methods can dramatically influence the genetic stability of stem cells, even over
relatively short culture periods [40,41]. Accordingly,
a means of monitoring genomic stability is important for cell bank testing. Karyotyping by Geimsa
banding is the technique most commonly performed, as this can identify changes in chromosomal numbers as well as translocations and other
rearrangements. Demonstration of maintenance
of a diploid karyotype at a certain passage number
(e.g., every ten passages or equivalent population
doublings) will be of value. Array comparative
genomic hybridization is now increasingly used
in clinical diagnosis and offers significant benefits in terms of the size of genetic lesions that
can be detected, although it will not recognise
some aberrations such as balanced translocations.
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Other genomic information derived from techniques, such as chromosome painting to identify
aberrant chromosomes (e.g., spectral karyotyping, fluorescent in situ hybridization [FISH]) and
deep sequencing can also be considered [42–46],
however the sensitivity of these methods should
be evaluated alongside the level of resolution of
genetic changes and the availability of suitable
controls. Analysis of wide ranging gene expression profiles has also been proposed as a means
of virtual karyotyping and detection of genetic
instability [47].
It may be useful to perform copy number analysis of certain sequences since there is evidence
that specific lesions (deletions and duplications)
are found repeatedly at specific genomic regions
[47]. Copy number analysis can be performed
using SNP or comparative genomic hybridization
microarray analysis, as well as sequencing across
the region of interest. However, the biological
significance of gain or loss of small regions of the
genome remains to be defined and such changes
may arise in the donor population [37].
The epigenetic status of undifferentiated
pluripotent stem cell lines has been widely
investigated, but it is currently difficult to set
standards for stem cells [48,49]. DNA methylation studies have not yielded clear and consistent results with respect to stability. However,
it is known that culture conditions can strongly
influence DNA methylation [50–53]. Microarrays
now allow affordable high-resolution genomewide DNA methylation analysis [52]. In the case
of hiPSCs created from somatic cells, DNA
methylation patterns might be an approach to
determine whether cells have been completely
reprogrammed from parental lines. For a review
of epigenetic instability in hPSC lines see [26].
As part of the evaluation of a stem cell line for
its suitability to deliver cell therapies, it will also
be helpful to demonstrate that it is possible to
passage the cell line up to or beyond the number
of population doublings under conditions which
replicate or simulate the actual production culture
expansion process. Such qualification and testing (e.g., phenotype, ultrastructure, virology) is
prescribed by the WHO for cell substrates used
for the manufacture of therapeutics and vaccines,
which also considered the potential requirements
for evaluation of stem cell lines for use in humans
[3] (see also section 8.1).
4.2.2 Genetic stability testing

The requirement for karyological testing of seed
stock may differ from the requirements for final
product cells used in the manufacturing process.
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The requirement for karyological analysis of seed
stocks will depend on the characteristics of the
cell line in question (e.g., its degree of genetic
stability). It is considered sufficient for seed
stocks that data on 20 Geimsa–banded metaphase spreads be provided and to have chromosome counts on a further ten metaphase spreads,
as proposed for research grade cell lines [1]. This
will enable the detection of karyologically abnormal cells at the level of 5%, although certain
abnormalities may not be detected.
Certain levels of genetic abnormality may
be acceptable in undifferentiated seed stocks,
provided there are procedures that eliminate
abnormal cells or any related hazard in cells for
final clinical use. The recommended criteria for
karyological screening of seed stocks is given in
Table 1. However, cells to be used in cell therapy
products will need to be evaluated on a case by
case basis with respect to the karyotype.
Whilst karyology is the current reference
method for evaluating genome integrity, it may
not be sensitive to small genetic changes. A
number of important new techniques for characterising the genome include spectral karyotyping, comparative genome hybridization (CGH)
microarray, SNP microarrays, and whole genome
sequencing. These offer the opportunity to analyze and understand changes in the genome at
different levels of resolution. While these are still
essentially research tools, CGH microarray is
now becoming qualified for diagnosis of genetic
disorders [54] and could be the first of these techniques used for lot release by stem cell repositories.
However, it should be noted that this technique
does not detect balanced translocations and it is
best practice that any genetic aberration detected,
is validated using FISH. In general, these techniques could benefit the characterization of stem
cell lines intended for clinical use, but would be
for ‘information only’ rather than release criteria.
A better understanding of the levels and
types of genetic instability of each type of cell
culture and the potential impact on safety of
the final product will clearly be important but
is still developing. Repositories of stem cell lines
should keep abreast of current developments
e.g. through recruitment of appropriate experts
for their advisory board.

4.3 Tumorigencicity versus
pluripotency
General considerations on evaluation of
tumorigenicity

The inoculation of cells into an immune-compromised host animal has been used for many
future science group
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years to evaluate the ability of different cell
types to form or cause tumors as an indication
of potential risk associated with the use of such
cells to make therapeutic products and vaccines.
Animal cells have been considered to have two
types of capability to cause malignancy: first,
tumorigenicity, by which the cells grow in a
host organism in an uncontrolled way to create masses of cells; and second, oncogenicity, by
which cells or the components of cells are able to
induce malignant growth of the host organisms
cells. Clear definitions for tumorigenicity and
oncogenicity have been established for such testing in cells used for manufacture of products [3]
and also proposed for use in cell therapy [2]. The
same types of test methods are also used to assess
the potential pluripotency of stem cell lines and
some methodologies have been proposed as standards for assessing this property of hPSC lines
[55]. The reproducibility and standardization of
assays has been debated for many years [56], but if
they are to be used it is important for the investigator to be absolutely clear on the objective of
the test and standardized methodology for the
intended purpose (tumorigenicity, oncogenicity
or pluripotency), and to have clear criteria for
assessment of the results. Of course, it should not
be forgotten that the utility of teratoma formation from hPSC lines in mice is not just in the
assessment of tumorigenicity, but also in providing potentially valuable tools for investigation of
early human development [57].
4.3.1 Tumorigenicity testing

As for pluripotency testing (below), there has
been tremendous variation in assays for in vivo
tumorigenicty testing. The minimum inoculum
dose is not standardized, but in many protocols
106 –107 cells are injected, in clusters, per animal.
It is believed that the preparation of the cells and
the site of inoculation could have a significant
influence on results [58,59]. The strain of mouse
could also influence the outcome of tumorigenicity assays due to differences in physiology
and immune status. In the ISCBI survey (see
Appendix 9) seven different strains of immunedeficient mice were reported in use, some of
which retain certain immune cell functions.
For tumorigenicity testing mouse strains with
multiple immune deficiencies, including lack of
functional T- and B-lymphocytes and NK cells
are recommended, including NOG (NOD/Shiscid/IL2Rgnull) [60,61] and also the NGS [263]. In
addition, the time period of observation of inoculated animal and its predisposition to develop
spontaneous tumors may also affect results of
www.futuremedicine.com
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Table 1. Standard methods, procedures and recommended terms for the reporting of the karyological analysis
of undifferentiated human pluripotent stem cells.
Karyological analysis of pluripotent stem cells
Standard Geimsa-band analysis

Examination of metaphases with eight metaphases analyzed (minimum) and 20
metaphases counted (ISCBI, 2009)
Clonal abnormal findings
Confirmation of clonal chromosome abnormalities in a later cell culture passage or
calculated population doublings
Abnormalities observed in single cells
Aneuploidy of chromosomes
Aneuploidy of chromosomes can be observed in pluripotent cell lines with most common
occurrence for chromosomes 1,8,12,14,17 and X
Analysis of a minimum of 30 G-banded cells counted from initial culture (ISCBI, 2009)
Follow-up analysis of a further 30 G-banded cells taken from a later passage cell culture
in combination with the examination of 100 interphases using fluorescent in situ
hybridization (FISH) with a relevant probe
Other aneuploidy and structural abnormalities
Analysis of a minimum of 30 G-banded cells counted from initial culture
Minimum quality score
Minimal level of G-banding analysis for hESC lines for research purposes was published
previously (ISCBI, 2009) and was developed from the International System for Human
Cytogenetic Nomenclature (ISCN) in which analysis to Band level 400 was recommended
with an expectation that analysis of band level 500 or above would be attempted
See also Professional Guidelines for Clinical Cytogenetics General Best Practice Guidelines
(2007) v1.04 March 2007
Sub-standard analysis
Failure to attain an ISCN 400 level of banding can be reported with the proviso that the
analysis may need to be repeated
Reporting the results
The report should contain:
The karyotype description stated using the current ISCN nomenclature 2009
The type of analysis used e.g., fluorescent in situ hybridization, type of banding
The average banding level attained
Single cells displaying aneuploidy or structural anomalies should be reported. Cells should
be analyzed again after extended passaging (or high population doublings) in culture to
investigate and interpret the abnormality
Definition of terms (taken from the Association Analyze: To count a metaphase and compare every chromosome, band for band, with
for Clinical Cytogenetics Professional
its homologue and to verify the banding pattern of the X and Y-chromosomes in male
Guidelines for Clinical Cytogenetics, General
karyotypes.
Best Practice Guidelines [2007] v1.04)
Clone: A cell population originally derived from a single progenitor cell. Such cells will
have an identical chromosome constitution. Generally, in cytogenetics, a clone is said to
exist if three cells have lost the same chromosome, or two cells contain the same extra or
rearranged chromosome.
Count: To enumerate the total number of chromosomes in any given metaphase, or in
FISH analysis to enumerate the number of signals in an interphase nucleus.
Examine: To look for the presence or absence of any abnormality in a case.
Score/screen: To check for the presence or absence of abnormalities in a cell or
metaphase without full analysis.
Adapted from [1].

tumorigenicity assays. A standardized method
was recently published by the WHO for evaluation of tumorigenicity in cells used for vaccine
and biotherapeutic manufacture [3], but whatever method is used it will need to be optimized
for detection of tumorigenicitiy in pluripotent
stem cell lines.
The role of assays specified to optimise detection of potentially malignant tumorigenic cells
has not yet been established for hPSC lines.
Teratoma assays established to evaluate pluripotent potential of a culture are not designed
to detect low levels of transformed malignant
10
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cells. However, the possibility to detect such
cells present at a significant level in in vivo
pluripotency assays should be born in mind
when reviewing teratoma assay data. For in vivo
tumorigenicity testing it will be important for
such analysis to be performed by a qualified
histologist familiar with the morphologies of
teratoma (benign) and teratocarcinoma (malignant) cytology and tumor formation. In addition, as prescribed for general good cell culture
practice (GCCP) [63], it may also be valuable to
carry out routine microscopical screening of
cultures for abnormal cells.
future science group
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Specially designed tumorigenicity assays that
can detect low levels of tumorigenic cells, will
also be important for cell therapy products [64,65];
however, this is out of the scope of the current
document.

4.4 Genetic disorders
4.4.1 General considerations on inherited
genetic disorders

The genomes of any donor of tissue for generation of hPSCs, will contain sequences that are
associated with predisposition to disease. However, it is relatively rare that such sequences
become expressed in the individual’s phenotype,
or otherwise develop (such as disease associated
with expansion of DNA microsatellite repeats),
and cause disease in the individual carrying the
affected sequence. In addition, certain HLA
allele haplotypes have autoimmune disease associations (e.g., diabetes, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, celiac disease), but obviously donors with the
disease-associated HLA alleles do not necessarily
develop disease.
The detection of a genetic attribute or variation in a donor is likely to mean that this is present in the stem cell line. However, as already
mentioned, pluripotent stem cell lines are known
to acquire genetic and epigenetic changes during
derivation and culture, thus, they may have more
potential abnormalities than may be found in the
donor. The real level of risk from these or other
identified disease associated genetic variants to
the functionality of cell therapies is uncertain.
A possible exception to this may be where tumor
suppressor genes, oncogenes or miRNA genes
are altered or overexpressed, rendering the host
cell potentially tumorigenic [66]. This obviously
would need to be considered in safety assessment
of the cellular products intended for therapy.
4.4.2 Genetic screening for diseaseassociated sequences

As discussed above and in section 3, the final
impact of a genetic or epigenetic lesion in the
donor in most cases will be unknown and testing for disease associated genetic variations will
generally not be helpful, unless the donor comes
from a genetic line or population that suffers
from a genetically inherited trait [9]. Current
experience in therapeutic transmission of disease predisposition is currently limited to cell
and tissue transplantation, predominantly from
one donor to one recipient. Future experience
with single cell lines developed for many patients
will be needed to identify any real genetic risk
future science group
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factors. However, as also briefly discussed in
section 3, it may be useful to screen for altered
genes (oncogenes, growth factors, etc.) in cell
lines. The Center for iPS Research and Application (CiRA) Institute in Kyoto has published a
list of oncogenes as a basis for such screening of
hPSC lines, and microarray technology provides
the means to do this routinely. Whole genome
sequencing of cell lines intended for clinical use
is generally agreed to be desirable to develop our
scientific understanding of these cell types and
repositories should seek to develop such data.
However, given the issues of potential for donor
identification (see above), repositories should
establish policies and procedures for release of
such data, that will oblige recipients of repository
data to use it in a way that would not increase
risk of donor identification [11]. Furthermore,
in order to avoid presenting misleading data
on cells for clinical use, repositories should also
seek to assure that best practice has been applied
in developing any genetic data they publicise.
In particular, whole genome sequencing still
requires development of appropriate standardization, without which the data should be considered to be research data for information only
and not necessarily relevant at this stage to establish suitability of lines for clinical application.

5. Characterization of hPSC seed
stocks

5.1 Cell identity
It is part of GCCP [63] to authenticate cell lines.
Cell line authentication is a critical step in the
banking process, assuring that a cell line is not
cross-contaminated by another line or otherwise
misidentified. Methodologies for individual
specific genetic identification have been standardized within the field of forensics, and commercial services and kits are readily accessible
as described in the guidance on research grade
cells [1]. These kits typically comprise primers for
up to 16 short tandem repeat (STR) DNA alleles
with 5 or more of these alleles in common which
can be utilized to facilitate direct comparison of
cell line profiles even when generated by different repositories using different kits (see [1] for a
comparison of STR alleles shared between commercial kits). Such comparisons are not so readily achieved using other genetic identity testing
techniques such as SNP analysis. It is advised
that the STR testing be performed in accordance with the Authentication of Human Cell
Lines standard ANSI/ATCC ASN-0002–2011
[67,201]. This standard advises the use of 8 STR
loci with a match threshold of 80% to ensure
www.futuremedicine.com
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specific identification of the line. Reporting of
DNA profile data should be considered carefully
as donors could be identified [11,68].
In the case of multiple cell lines isolated from
the same embryo or donor tissue, DNA fingerprinting is not likely to discriminate between
such cell lines. It is important that such clones
are identified clearly in their naming [69]. However, some means of demonstrating their unique
identity will be required and if this is not possible by molecular analysis the mechanisms
used to ensure the physical isolation of cell lines
during culture should manage the risk of lines
that have the same identity profile, becoming
switched (see section 6.4).

Viability and measurement of
growth
Special care should be given to choosing the time
point at which viability tests are performed, as
tests taken immediately after thawing may overestimate viability. It is therefore important for the
repository to gain experience in assessing postthaw viability and survival of colonies under its
own culture conditions. Regulators and others
have addressed the idea of setting acceptability
limits for viability, but this has proven difficult as
it may be process and cell type-dependent. A range
of other tests such as propidium iodide, neutral
red assay, fluorescein diacetate or alamar blue may
be used, but each give data on a different aspect of
cellular fiunction. Other regulatory guidance on
cell substrates used for manufacturing purposes
[3], councils that the method of viability testing,
and the levels of viability considered acceptable,
should be established based on their suitability for
the specific cell types in question and scientific
knowledge of the cell type. This latter position
is especially relevant for stem cell lines. Finally,
it is important to recognise that viability does
not necessarily predict desired functionality of a
cell preparation, which must be demonstrated by
other means (see section 5.3 & 5.4).
The nature of growth measurements will
depend on whether cells are passaged as single
cell suspensions or colony fragments. Single
cell suspension passage is the more convenient
and more efficient technique, but will require
validation in each laboratory to assure that the
genetic stability and pluripotent potential of the
stem cell lines is not affected. Growth rate is an
important characteristic that needs to be monitored using population doublings where possible,
as an increase in cell replication rate may indicate transformation. Switching growth medium
may affect growth rate, but this would typically
12
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be reversible on return to original medium, if
the cells have not become transformed or permanently altered in some other way. Alkaline
phosphatase-positive colony-forming assays may
also be useful for quantitation of growth of stem
cell lines [70].

5.3 Characterization of gene and
antigen expression
Characterization of gene and antigen expression
provides useful fundamental information on cell
state and the variability and consistency of cultures, especially where assays allow many targets
to be evaluated simultaneously as in microarrays
(e.g., whole genome expression arrays [Illumina,
Agilent or Affymetrix], TaqManTM Low Density
Array cards, ScorecardTM [LifeTechnologies])
and the multi-flourochrome labelling of cells.
There are a range of antibody-based markers that
are used for identification of different stem cell
types [71] and further markers may be useful to
qualify the nature and state of pluripotent stem
cells [72].
It is well known that pluripotent stem cell
cultures vary in gene and antigen expression
from one passage to another [73], but a stem cell
repository should seek to set acceptable ranges
for expression in the culture systems they use.
Typical surface antigen markers that may be
used to monitor phenotypic stability are indicated in Appendix 6. Control cell cultures are
useful to run in parallel with undifferentiated
cell lines and in number of settings the 2102Ep
embryonal carcinoma cell line has been recommended for this purpose as it shows stable
expression of common hPSC markers [73–75].
However, pluripotency assays have greater value
in that they provide an indication that the relevant functional capabilities of a pluripotent
stem cell line remain unaffected by the banking
process (Appendix 6).
To assure the quality of reprogrammed cells
it is important to demonstrate that expression
of exogenous reprogramming factors has been
silenced or removed. In retroviral systems, that
are unlikely to be used in cells for clinical application, incomplete silencing is an indicator of
partial reprogramming and checks for sustained
silencing of exogenous factors may be needed
with less optimal vector systems. For non-integrating reprogramming vectors, which in theory
are the most promising for clinical applications
[76,77], it is important to demonstrate silencing
and removal of the original exogenous expression
system (episomal viral construct or mRNA).
Accordingly, both antibody- and qPCR-based
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test methods are available for the commercially
available regprograming kits and qualification of
the sensitivity of these methods would be needed
if iPSC for lines were to be considered for clinical applications. It should be born in mind that
non-integrating virus constructs may persist for
a number of passages and testing is typically
performed between passage 5–10 after an iPSC
line has been established (see also Appendix 6).

5.4 Pluripotency assays
5.4.1 General considerations on
pluripotency

Teratoma assays to evaluate the pluripotency of
stem cell lines provide a valuable characterization
of the key functional feature of these cells (i.e., the
benign tumors exhibit tissue representing all three
germ layers required to form the human body).
However, responses to a survey by the International Stem Cell Initiative (ISCI; see Appendix 9
for details) and other reports [79] have revealed significant variation in methodologies used to perform the teratoma assay, which might be expected
to influence the ability to compare data from different Centers directly. The range of parameters
that may affect the reliability of teratoma data,
including the strain of mouse used, are consistent
with those which may influence tumorigenicity
assays as discussed in section 4.3.2. An approach
to develop a standardized tumorigenicity assay
has been proposed by Gropp et al. [55].
A number of papers have been published [78–
80] proposing assays using a transcriptome-based
bioinformatic approach. Alternative ways of analysing the pluripotent properties of cells is an
active area of investigation, and methods including gene expression profiling of differentiating
cells in vitro in embryoid bodies or earlier phases
of induced differentiation, or the analysis of epigenetic status [52,81,82] are being considered. Pluripotency can also be characterized by formation
of embryoid bodies in vitro and gene expression
or immunological marking of the three germ layers, or use of directed differentiation protocols.
These are also being used in combination with
gene expression systems to provide assays that
could replace the use of teratomas [56].
5.4.2 Pluripotency testing

Pluripotency assays can be used to give an indication that the cell line has not been altered by
in vitro culture, although it should be recognised that they are not conclusive for pluripotency in this respect (i.e., demonstrate the cell
lines capability to generate all cells of the adult
human body or that the cell retains normal
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differentiation pathways). Testing using one or
a combination of assays for pluripotent potential
qualified by the stem cell repository (see Appendix 6) may, therefore, give an indication that
the cell line has not been affected by its derivation and culture history and retains a potentially
broad range of capability for cell therapy. Conversely, it may be concluded that a purported
pluripotent cell line that fails to demonstrate
potential pluripotency may have been isolated
from cells that were not fully pluripotent or has
undergone deleterious changes during isolation and culture. For this reason, and also to
assure broad potential applicability in therapy,
it is therefore recommended that stem cell lines
should be assessed for pluripotency.
At this time it is not possible to make firm
conclusions about the most suitable methods
to use as a pluripotency assay for seed stocks
intended for clinical use. Stem cell line repositories will need to consider what method is most
appropriate to confirm the desired characteristics of the cells they release. Ideally, more than
one assay type would be used, that in combination reveal different aspects of pluripotency,
that is, the ability to show molecular evidence
for the ability to commit to all three germ line
lineages, but also to create cells representative
of certain tissue phenotypes typical of the three
germ lineages.

6. Regulation and quality assurance

Quality assurance: general principles
Stem cell repositories providing cells intended
for use in humans require an established quality
assurance (QA) procedure providing a formal
methodology and due diligence, designed to
afford adequate confidence that the entire operation will fulfil expected and defined requirements for quality of seed stocks of pluripotent
stem lines. A quality management system
(QMS) should be implemented that describes
the organisational structure, responsibilities,
policies, procedures, processes and resources
required for QA [84]. The QMS should be based
on the principles of current good manufacturing practice (cGMP) [83–87], and should consider relevant local regulatory requirements and
guidance. However, such systems are not necessarily required to be performed under a GMP
manufacturing license, but should meet a certain standard (such as the European Union Tissues and Cells Directive, EUTCD [88], which
assures suitability of the stem cell repositories
for clinical application and critically establishes
traceability for all materials and procedures
www.futuremedicine.com
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used from the point of informed consent for
procurement of primary tissue, to the final seed
stocks. All critical procedures used in delivery
of the seed stocks should be documented as formally recorded standard operating procedures
(SOPs), associated forms and higher level documents such as policies, process descriptions covering a number of SOPs, manuals and training
documents. All critical records should be controlled to assure that only the correct and current
procedures and forms are used and that old versions are archived carefully to allow review and
audit in the future. Regulatory requirements will
also apply to storage and retention times for the
repository’s critical records including those for
procurement, facilities, staff training, banking,
testing, storage and distribution.
Definitions of terms used in QA are important to enable the user to comply with the
regulation. Appendix 7 shows examples of
such definitions but it should be born in mind
that, whilst the terminologies used are broadly
consistent, there can be significant differences
and the user is advised to check the national or
locally applicable terms.

6.2 Risk analysis
Stem cell repositories should adopt an appropriate risk evaluation model to identify and manage
risk within the operation. This process usually
involves the maintenance of a risk register to
ensure the ongoing monitoring of risk. Repositories should use risk management to ensure effort
in assessing risk is appropriately focused. While
not limited to these items, a risk management
system should as a minimum:

Identify and evaluate risks and compile a risk
register (of note, risk assessment of reagents
and processes can be managed within the
Quality System [see section 6.1]);

Score and prioritize risks;

Assess residual risk after application of controls already in place;

Develop action plans for any unacceptable
residual risks;

Regularly review for change and identify new
risks.
New risks may be identified through various
routes such as regulatory alerts and reviews of
emerging diseases. Stem cell repository scientific advisory boards should be used to help identify new risks as part of their horizon scanning
activity.
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6.3 Risk assessment of donor tissues
and critical reagents
6.3.1 Donor tissues

Key issues and approaches to microbiological
risk assessment of donor tissues have already
been considered in section 4.1.1. In addition,
evidence for lack of susceptibility of stem cells
to certain agents can be used to give confidence
in suitability for clinical use, but these susceptibility profiles have yet to be established for pluripotent cells and their differentiated progeny.
Recommendations for the evaluation of cell
substrates for production of biologicals, including vaccines and biotherapeutics [3,14] have
identified key issues for risk evaluation of cell
lines, and these may be helpful in establishing
testing regimes for seed stocks of hPSC lines.
The WHO document [3] has also addressed
some of the key issues for evaluation of stem cell
lines for the manufacture of biological products
(see section 8.1). However, regulatory documents intended for use with the manufacture
of different kinds of products should be used
with caution to avoid implementation of inappropriate or unnecessary quality control and
safety testing procedures.
6.3.2 Critical reagents

Critical reagents in the preparation of seed
stocks of hPSC lines, for the purposes of this
document, include those materials used in the
generation of hPSC lines and the production of
cell banks that come in direct contact with, or
otherwise could have a critical influence on, the
properties and safety of the resulting seed stocks.
Process maps, such as that given in Figure 1, are
valuable in enabling a complete understanding
of the derivation and cell banking process (and
any other process to which they are applied),
including identification of all critical reagents
used and key points where cells may be exposed
to contamination.
Repositories should establish a specification
and acceptability criteria for all raw materials,
including the original cell lines if not generated
by the repository itself. They should also consider auditing suppliers of raw materials [89,90] to
assure compliance with these specifications. This
can be an extremely burdensome process and
may need to be managed, such that the repositories resource for performing its own audits can
then be focused by risk assessment. These should
address risk factors such as the absence of formal
supplier audit, inappropriate or inadequate QA
and suppliers of complex biological reagents of
biological origin.
future science group

Development of seed stocks of pluripotent stem cells for clinical applications

Human
embryo

IVF process

Human
tissue

Cultured
1–3 days
Macerate
Digest

Store
Thaw
Pronase treatment
CPA elution and washing
Immuno
surgery

Freeze

Thaw

P1

Sub culture

*Mitomycin C
γ-irradiation

BRL cells

CPA elution and washing
Thaw cells

Store frozen

Remove
medium

P3

Culture
cells

Store cells

hES
medium

Freeze

Sub culture

P2

Feeder
treatment*

Thaw
medium

hES
cell line
derivation

Freeze
Washing and CPA addition

Feeder
layer
BRL conditioned
medium

ICM

hES culture
processes

hFS
primary
derivation
Fibroblast
expansion

6 day
embryo

Thaw
Store

Freeze

Cultured
1–3 days

CPA elution and washing
Thaw

Wash

Washing and CPA addition

Supplement

Culture cells

Freeze cells
Washing and Cp addition

Sub culture

Figure 1. Example of a process map for derivation of a human embryonic stem cell line.
Courtesy of C Hunt, UK Stem Cell Bank, NIBSC, 2013.

It is important to establish a ‘document trail’
for critical reagents. The documents should be
available from the supplier, who ideally should
be able to trace the source of raw materials used,
how they are processed, treated and shipped.
However, this may not always be the case.
Accordingly, the development of a supplier
questionnaire should be considered. With this
in mind the following list, while not exhaustive nor necessarily sufficient for any particular
regulator process, is intended as a guide to the
kinds of issues that may need to be addressed
when soliciting information from a supplier
(section 6.8) and assist in prioritizing the need
for a repository to audit suppliers as discussed
above:

Details of the supplier: name, address, telephone number, principal contact and position;

General information:
-- Description of function e.g., manufacturer,
distributor etc.
-- Does the supplier sub-contract, and if yes,
future science group

how is control of the subcontract and
materials achieved?
-- Is there a supplier audit programme or
vendor rating scheme in place, and how is
this monitored?
-- Are customers informed of changes to
their products and how is this information
transmitted?


Quality Management System (QMS):
-----

Is there a QMS in place?
Is there an internal audit programme in place?
Is there a document control system in place?
Is quality documentation issued with the
product (e.g., Certificates of analysis)?
-- Where applicable, are certificates for animal
derived/origin products provided?
-- Are there procedures in place for calibration,
verification and maintenance of equipment.
-- Is there a procedure to communicate
regulatory alerts to customers?


Product Specification questions:
-- Name of product/catalogue number
-- Is QC performed on the product and is this
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carried out by the supplier themselves?
-- What type of QC is carried out and what are
the pass/fail criteria?

In order for the questionnaire to be of value
it should also include the date it was completed
and details of the person completing it on behalf
of the supplier and any relevant documentary
evidence to support the answers to the questions.
Supplies of cells used to facilitate the culture
of hPSC lines (e.g., feeder cells, cells used to
make cell-conditioned medium or other product) should also be subjected to similar evaluation and risk assessment.

6.4 Seed stock and clinical trial cell
bank production and labelling
The suggested structure for an appropriate twotier cell banking system (MCBs and WCBs, see
section 4) is outlined in ISCBI [1]. Sufficient vial
numbers should be established to meet anticipated demand for seed stock cell supply and
testing that may be required in the near future
(i.e., next 5–10 years). Contingency to allocate
seed stock vials for additional testing that may
be needed will be important. Furthermore, past
experience in cell banking for cell lines used
to manufacture vaccines and biotherapeutic
products, has shown that it can be extremely
valuable to allow for some additional production contingency vials. While it is difficult to
prescribe numbers of these additional vials, some
contingency will enable immediate response to
a sudden increased demand for testing or for
production cells and avoid delays caused by rebanking in the future.
If repositories are providing cell banks
that are to be used to provide material direct
into a clinical application (e.g., clinical trial,
EU hospital exemption) they would usually
be expected to do so under a Manufacturing
License with GMP accreditation. This requires
careful environmental controls [91] and other
more specific requirements, depending on the
local jurisdiction [84,87,92]. A glossary of terms
commonly used in GMP production can be
found in Appendix 7. However, it is important
to note that precise definitions of particular
words in this glossary may vary between regulators, accordingly, Appendix 7 is provided as
an example only. Repositories should be aware
of local and international regulatory requirements, which will apply to all aspects of the
facility, including movement of staff and materials, staff health status and other activities or
services which in particular, could introduce
contamination.
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It is essential to assure that cell lines do not
become switched or transmit microbial contamination to other cells used in the banking and
storage facility. Accurate labelling (see below)
and documentation of cell handling processes
are clearly vital to this and in addition preparation of cell banks of different cell lines on a ‘campaign’ basis (i.e., one cell line per laboratory at
any one time with qualified cleaning completed
between banking events).
All repository systems and equipment that
may affect the final seed stock quality must be
monitored for operation between limits established for validation (section 6.5), and alarmed
to warn when out of specified conditions. Where
temperature limits are key to the process (e.g.,
to prevent storage at inappropriate temperatures)
the equipment should be alarmed and upper
(and where appropriate lower) limits set. Alarms
for other parameters, (e.g., low liquid nitrogen
[LN2] levels, failure of LN2 supply) should also
be in place.
Importantly, stem cell lines and products
incorporating viable cells cannot be terminally
sterilized, and it is therefore vital that the conditions of cell banking do not introduce microbiological contamination or permit growth of any
microorganisms that might already be present.
Cell culture rooms must be operated to ensure
environmental contamination is controlled to
acceptable levels prescribed in appropriate legislation [83,84,86,88]. In addition, documented procedural controls will be required to reduce the
risk of introducing or spreading contamination
and cell banking records should be able demonstrate that the appropriate procedures were used
in each case. Both physical and chemical means
of disinfection may be employed as appropriate
for specific facilities and equipment. The cleaning and disinfection procedures should also be
validated to show they are effective against likely
contaminants.
Labelling is a critical element in assuring
traceability of materials. Repositories should
aim to adopt appropriate labelling systems to
fit the developing norms for supply of cells for
clinical use. The Information Standard for
Blood and Transplant (ISBT) 128 system [202]
developed in the USA by the American Association of Tissue Banks, is now being considered as a model in other countries and whilst
unmodified hPSCs are not intended to be used
directly as therapeutic products, this example
could be considered as the basis of best practice
for labelling containers of individual release lots
of stem cell lines.
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6.5 Validation
All repository processes, equipment and facilities should be validated to demonstrate they are
fit for their intended purpose. Validation is the
documented act of ensuring that any procedure,
process, equipment, material, activity or system
actually gives the expected results with adequate
reproducibility [87]. This approach should include
implementation of the key elements of validation
including a user requirement specification (URS),
impact/risk assessments, and a series of qualification stages for equipment (i.e. design qualification
[DQ], installation qualification [IQ], operational
qualification [OQ], and performance qualification [PQ]). Repositories may also use a validation master plan that describes the overall philosophy, strategy, and methodology for validation,
and which equipment, processes and other items
require validation. A validation matrix or schedule of validation will also be useful to document
which organisation or contractor is responsible for
each item subjected to validation. It is important
that risk assessments are performed in advance
of validation to ensure critical areas are targeted
and that any validation performed is appropriate
and optimised in terms of use of resource. Due to
commonality of operations this is an area where
exchange of learning experiences between repositories can help to reduce the burden of QA.
Validation should be considered for any equipment used that may impact on the suitability of
the cell banks for clinical use, such as that used
in processing, cleaning, environmental monitoring, storage and shipment. Equipment such
as controlled-rate freezers, mechanical refrigerators, LN2 storage refrigerators and dry-shippers
will require appropriate monitoring, such as continuous temperature monitoring and recording
when in use, to demonstrate that the required
conditions are maintained. Shipment devices,
such as ‘dry shippers’, will also require validation
to assure fitness for purpose. Critical equipment
such as heating, ventilation and air conditioning (HVAC), biological safety cabinets, particle
counters, incubators and cold storage should be
validated. The Pharmaceutical Inspection Cooperation Scheme [203] and WHO [87] both provide guidance on related validation, and compliance with national regulation.
Process validation in particular should be
considered on a case-by-case basis. Validation
of routine expansion and banking of cell lines
will need to take many factors into account,
including the number and type of interventions required, the culture format being used
(e.g., open or closed system), transfers between
future science group
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processing areas and incubators, and the impact
of different operators and different cabinets/
rooms. Within the banking process, the cryopreservation process itself should be validated
to demonstrate that cells recovered from cryopreservation have the characteristics set out in
the repository’s cell bank release specification
for cell lines.

6.6 Qualification and
standardization of test methods and
reagents
Establishing the testing regime for seed stock
banks has been described and discussed in section 4 and Appendix 6. All tests used to establish
suitability of hPSC seed stocks for clinical use
should be qualified for use. This qualification
should address requirements, including but not
necessarily restricted to, sensitivity, specificity
and also potential for effects (such as test inhibition) by the hPSC sample components. This
is most readily achieved by supplying samples
to testing laboratories accredited for the tests in
question. Where such accredited testing is not
available the repository should be able to provide qualification data for the tests performed.
Accredited services may be available that can
provide tests that meet multiple or harmonised
pharmacopoeia requirements and these may be
required where the cell line is to be used internationally [93].
Well established surface markers and a wide
range of gene markers are used in stem cell characterization, and selected reference materials for
their assay may be useful (e.g., fixed cell preparations, RNA preparations). Standardized functional assays will need to be developed, and in
particular standardized pluripotency assays will
be important to progress in the field as assays
and reagents vary between laboratories. The
ISCI has focused on a number of relevant issues
in this area, including the initial identification
of standard markers for hESC lines [73]. This
group has also begun to work on determination of pluripotency in hPSC lines and further
international collaborative effort is required in
this important aspect of pluripotent stem cell
research, which is fundamental to supporting
high-quality research data (see www.stem-cellforum.net). For an overview on standards in the
cell therapy area see Sheridan et al. [95] and for an
over view on cell characterization for cell therapy
see PAS 93 [93].
Of note, where reagents of biological origin are clinical products in their own right,
standardization of their biological activity is
www.futuremedicine.com
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often performed under the auspices of WHO
and its Expert Committee on Biological Standardization [205]. Most of the WHO International Reference Materials (IRMs) are made
and distributed by the National Institute for
Biological Standards and Control (a center of
the Medicines and Health-care Products Regulatory Authority [MHRA]) and a listing of
these materials can be found on the National
Institute for Biological Standards and Control
website [206].
Standardization of certain reagents such as
growth factors used in cell culture may also be
helpful to enhance reproducibility of cultures
of hPSC lines. This can in part be achieved by
the repository establishing specifications and
acceptance criteria for the properties of complex cell culture components. In addition, cell
culture assays and control materials can be
established to determine batch consistency in
supplies of such factors. Where such reagents
are used widely it may be feasible to establish
international reference materials (see previous
paragraph). Furthermore, for certain reagents
there are Pharmacopeia reference methods for
their characterization.

6.7 Auditing suppliers and service
providers
An important element in assuring traceability,
safety, and thus suitability for repositories of
hPSCs, is the performance of audits of suppliers of critical reagents and services that would
impact on the final quality of the cell lines
offered for clinical use. Such audits may range
from a paper-based audit (which may be justified where suppliers operate under relevant and
independently inspected quality standards) to
a detailed on-site inspection of procedures and
documentation. The sharing of such audits
between repositories could provide both costand time-saving benefits. However, implementing such a scheme would be challenging and
repositories would need to be confident in the
ability of any third party auditor and in the
consistency of the auditing procedure between
repositories. Recruiting a common auditor with
appropriate training and expertise using a common audit protocol is a possible solution. Such
an auditor should have previous experience
with inspecting similar facilities and operations and should have a regulatory background.
Alternatively, repositories may decide only to
use suppliers who are registered and inspected
by a recognised regulatory body; however, this
should be done using a risk-based approach.
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6.8 Cell line ‘history file’
Careful evaluation of the information associated with a stem cell line is necessary to determine its suitability for developing a clinical
product. Where the repository has derived
the hPSC line it can collate this information
directly under its own QMS. However, where
this is not the case it is important to avoid wasting time and resource on unsuitable cell lines,
thus, stem cell repositories should request relevant historical information from the depositor
and continue to build a documented history
pertaining to each cell line as it is processed and
banked. This compiled documentation, sometimes called a cell line ‘history file’, should provide all information necessary to enable traceability of cell line establishment and processing,
from the derivation and original transport to
the repository, through banking, testing, storage and any subsequent distribution. This history file should also include evidence that the
cell banking was performed under principles
of GMP or other suitable conditions where a
GMP manufacturing license is not applicable
(i.e., early seed stocks where a final product is
not identified, whereas MCBs and WCBs for
specific clinical applications in a clinical trial
or under Hospital Exemption arrangements,
would probably be required to be prepared
under a GMP manufacturing license). For
example, the EU directive on tissues and cells
for use in humans [88] is based on the principles
of GMP, but a manufacturing license under
EU GMP is not required for cells and tissue
intended for human application including seed
stocks of hPSC lines. Some of the key aspects
that should be considered for inclusion in a cell
line history file are given in Table 2 . Whilst it is
unlikely to be feasible to include all raw data
and original information, the history file should
at least facilitate traceability to that information. Where the cell repository receives the cell
line from a depositor working under a suitable
quality system, the repository may decide that a
documented audit (physical site audit or paper
based) along with traceability (typically an
anonymized link) to the donor and appropriate informed consent may be sufficient. Where
such links are not possible the repository will
need to carry out a risk assessment with respect
to the acceptability of that line within its own
jurisdiction and if contingencies cannot be put
in place to resolve significant risks then the
repository may decide not to receive the line
or supply it for restricted purposes such as for
laboratory research only.
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Table 2. Examples of information that may be required in a cell line history file.
Section

Typical content

Depositor information

Name of owner of cell line
Address (registered company and manufacturing sites where applicable)
Primary contact
Telephone number(s)
Evidence of ownership*
Signed records of inventory shipped and cross check of received goods, including ‘chain of
custody’ documentation
Records of temperature monitoring data
Record of courier used
Record of arrival at repository including transport time/temperature and condition on
receipt
Donor information related to the donation of primary tissue**
Original, anonymized donor consent and medical history (this may not always be available
depending on national laws and regulations)
Description of the culture conditions related to (where applicable): tissue or embryo
culture; cell line derivation; cell line expansion; reagent documentation, traceability
and cryopreservation. This should include, for example, passage number (or population
doublings where possible) of seed lots and subsequent banks that were created up to the
point of manufacture relevant to the material being received by the repository
Characterization and safety test results both provided by the depositor and generated by
the repository and given with associated passage or population doubling levels
Qualification records: records of use, maintenance, calibration, validation, re-verification,
repair
Records of and trends in scores of contamination for testing applied to the environmental
conditions, which may include: viable and non-viable particle counts; active air sampling,
air pressures, temperature, relative humidity, operator finger dabs, ambient temperatures in
critical storage areas
Records of deviations from normal procedure, which may affect the specific cell line, for
example failure of an incubator in which the line was processed
Records of change control investigations relevant to the cell line, for example impact of
changes to QC test specifications or moving storage location of cryopreserved material
Records of training and return to work procedures to ensure staff infectious status is not a
risk to cell cultures

Shipping records

Provenance

Culture/banking details

Quality control test results
Facility and equipment details
Environmental monitoring records

Deviations from standard procedures (SOPs)
Change controls
Records of staff training and illness of an
infectious nature

*There is a risk to final clinical utility of a particular cell line if all potential owners are not identified at an early stage. Thus, it is important to obtain accurate
information from the cell provider, about all parties with a potential interest in ownership of the cell line (e.g., sponsors of research, host organisation, principle
investigator) and to confirm, first, that they are in agreement with the repository receiving and distributing the cells, and second, whether they need to be a signatory
party to the deposit of the cell line in the repository.
**Detailed donor information may be held by the repository, but special care will obviously need to be taken (and may be a legal requirement) for its control and
security. For example, in the UK the Caldicot Principles apply to the management of sensitive patient data [215].

Over long periods of time, after the seed
stocks of cells have been released, quality
control data may become summarized and/
or archived by suppliers and service providers,
which means that its retrieval from the original
source is not practicable or not possible. It is
therefore important to endeavor to anticipate
the kinds of critical information that may be
required many years into the future (e.g., details
of quality control, information on production
processes, safety testing data), and obtain and
store copies of this from the respective sources
(e.g., raw material manufacturers, testing companies) when the cell line is banked, to form
part of the cell line ‘history file’ whether the
cells are stem cell lines or some other propagatable cell type.
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6.9 Serious adverse reaction (SAR)
and serious adverse event (SAE)
reporting
Events may arise during the provision of cells for
therapy that indicate potential risk to patients.
Whenever such events are identified, they are
required to be investigated for impact on the
patient and if necessary action taken to minimise the impact and prevent re-occurrence. Two
kinds of event are generally recognised, a serious adverse reaction (SAR) and a serious adverse
event (SAE). Whilst definitions of these may
vary significantly between regulators, a SAR
usually refers to a serious adverse reaction related
to treatment of a patient receiving the therapy
and a SAE refers to any other occurrences that
might have an impact on patients receiving the
www.futuremedicine.com
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therapy. Repositories clearly need to be aware of
the regulatory definitions that apply to them.
Most countries have established systems for
reporting post-donation disease and adverse
events in clinical trials. Repositories supplying cells that may be used for human application should be coordinated within these systems to ensure that SARs and SAEs related to
subsequent final products can be traced back
through the repository and ultimately to the
primary tissue donor to enable full investigation of the potential causes. Establishment of
mechanisms to assure traceability are critical
in the development of seed stocks, as already
discussed extensively throughout the earlier
sections of this document.
Stem cell repositories supplying cells for clinical use will be expected in the first instance to
identify, investigate and report SAEs occurring
in the banking process, which might affect the
suitability of the cells for clinical use. Second,
they will also be expected to submit to regulatory investigations when SARs or SAEs occur
in clinical applications using cells they have
supplied. In such cases, they will be expected
to demonstrate full traceability on the procurement, banking, testing, storage and supply for
the cells in question. It is vital that stem cell
repositories understand their responsibilities
in these situations and how to manage them
through appropriate elements of their QMS.
Within Europe, the Rapid Alert system for
human Tissues and Cells (RATC) has been
implemented whereby manufacturers (including ‘tissue establishments’ providing cells and
tissue as starting materials for cell therapies) and
distributors of medicinal products (including
advanced therapy medicinal products [ATMPs])
are required to report all SARs for medicinal
products (licensed, unlicensed and clinical trial
products) to their national competent authority
within a defined time period under RATC [207].
In the EU each national competent authority reports incidents to the Europe-wide pharmacovigilance web-based AE/AR collection
system EudraVigilance which is managed by
the European Medicines Agency (EMA). In
the USA, the FDA runs MedWatch [209] for
reporting and monitoring adverse reactions.
This includes specific guidance for human celland cellular-based tissue products. EU member
states are also required to report all adverse incidents to the WHO international drug monitoring programme and this is done by the national
competent authority. The WHO maintains an
international system for monitoring adverse
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reactions to drugs using information derived
from Member States within and beyond the
EU. The system is run and coordinated by the
Uppsala Monitoring Center (UMC) in Sweden (www.who.umc.org). Similar requirements
apply in other jurisdictions and a list of notified bodies in different countries is given in
Table 3 [208].
Stem cell repositories should consider the
International Conference on Harmonisation
(ICH) guidance on efficacy, which includes
guidance for pharmacovigilance planning and
definitions and standards for preparing and submitting safety reports [209]. Guidance can also
be obtained from the Council for International
Organisations of Medical Sciences (CIOMS)
[210], which was jointly established by the WHO
and the United Nations Educational Scientific
and Cultural Organisation.

6.10 Disaster recovery, contingency
planning and legacy management
It is necessary that procedures for disaster recovery are in put in place to manage unforeseen
events that may severely impact on repository
critical operations (e.g., fire, flood, loss of power,
failure of liquid nitrogen supply). Repositories
should at least maintain some local backup storage system such as splitting storage of stocks
over different equipment and locations. Such
backups must be maintained under the same
conditions as the main stocks. Where possible
repositories should encourage and advise depositors to secure their own cell stocks for backup in
this way. Records of banking inventories should
also be backed up and other critical repository
documentation on cell bank production either
backed up or adequately secured. In addition, it
is necessary to ensure that contingency plans are
in place to secure the continued availability of
stored cell lines for appropriate periods of time in
the event of normal repository operations being
discontinued. These procedures can be delivered
within a risk management system as outlined in
section 6.2.
A course of action should also be defined in
the event of a planned termination of the repository (such as an orderly wind-down when the
facility is transferred elsewhere) or an emergency
termination (including loss of key resources,
funding or regulatory approval). It will also be
important to distinguish between obligations
regarding cells intended for human application
and cells held for research, since the standards
and conditions required for both cells and
associated records will be different for each.
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Table 3. National competent authorities for serious adverse event and serious adverse reaction reporting.
Country

National competent authority

Program/website

Australia
Brazil
Canada
China

Therapeutic Goods Administration
ANVISA
Health Canada
National Institutes for Food and Drug Control
National Centre for ADR Monitoring
European Commission Rapid Alert system for human Tissues and Cells

www.tga.gov.au
http://portal.anvisa.gov.br/wps/portal/anvisa-ingles
www.hc-sc.gc.ca/index-eng.php
www.nicpbp.org.cn/en/CL0309

European

http://ec.europa.eu/health/blood_tissues_organs/
docs/ratc_report_2008_2012_en.pdf
Finland
Finnish Medicines Agency
www.fimea.fi/frontpage
France
French National Agency of Medicine and Health Products Safety, ANSM ansm.sante.fr/Produits-de-sante/Medicaments
Germany
Federal Institute for Drugs and Medical Devices
www.bfarm.de
www.bfarm.de/EN/Home/home_node.html (English)
India
Indian Pharmacopoeia Commission
www.ipc.gov.in
Israel
Israeli Ministry of Health
www.health.gov.il/english
Japan
The Pharmaceuticals and Medical Devices Agency
www.pmda.go.jp/english
Netherlands Pharmacovigilance Centre Lareb
www.lareb.nl
Singapore
Health Sciences Authority
www.hsa.gov.sg
South Korea MFDS
www.mfds.gov.kr
Spain
Spanish Medicines and Health Products Agency
www.aemps.gob.es/en
Sweden
Medical Products Agency
www.lakemedelsverket.se
Taiwan
Bureau of Medical Affairs, Department of Health and Center for Drug
www.fda.gov.tw
Evaluation
Thailand
US FDA, Drug Information Centre and NADRM
www.fda.moph.go.th
UK
Medicines and Healthcare Regulatory Agency
www.mhra.gov.uk
USA
US FDA
www.fda.gov


6.11 Regulation in different
countries
The regulation for cell-based therapies is still
at an early stage of development, and progress
in establishing formal regulatory frameworks
varies across jurisdictions [96]. As cell therapy
products are being developed, manufacturers
will aim to market their products in different
countries, making knowledge of the differences
in regulatory frameworks of vital importance. A
comparison of the regulatory frameworks in the
EU and the USA has been published by the British Standards Institute (PAS 83) [94]. The ISCBI
section on the ISCF website has also developed
information on the national regulatory bodies
(Table 3) and donor selection procedures in different countries (see Appendix 4), and provides
relevant policy statements by the ISCF Ethics
Working Party on cell banking procedures [5,11].
Some countries have developed regulatory route
maps to help national cell/tissue repositories,
hospitals, and industry negotiate the regulatory landscape, and a toolkit used in the UK for
stem cell therapy [211]. A route map regarding the
Canadian regulatory framework for the development of stem cell-based therapies has been developed under the auspices of the Canadian Stem
Cell Network [212].
future science group

7. Preservation and storage

7.1 Cryopreservation of hPSC lines
Cells can be stored in a stable state through the
application of appropriate cryopreservation protocols [96]. Cryopreservation includes a number
of processing steps both before low-temperature
storage and again at thawing and culture of
the cryopreserved material. In addition, material must be stored and transported under
conditions that maintain material stability.
Cryopreservation protocols generally fall into
two types: those that incur the formation of
ice within the system, whether intracellular or
extracellular (i.e. freezing) and those that avoid
ice formation (i.e. vitrification). For a review of
cryopreservation and vitrification methods [97].
In applying or designing an effective cryopreservation process, there are a number of key
technical issues that should be considered:

Methods for assessing recovery of cells from
the cryopreservation process

Choice of cryoprotective agent (CPA)

Choice of container and packaging

Mode of cryopreservation (i.e., freezing vs
vitrification)
www.futuremedicine.com
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Method of cooling (passive vs controlled rate
cooling)

Storage conditions

Transportation of cryopreserved material

Recovery process (i.e., rewarming and elution
of cryoprotectant)
7.1.1 Assessing recovery from
cryopreservation

In order to design or optimise any cryopreservation protocol, an assessment of recovery is
required. Tests using trypan blue or fluorescent
compounds such as acridine orange/ propidium
iodide are often referred to as ‘viability tests’,
but are more truly membrane integrity tests
[98]. The accuracy of these tests in indicating
normal function of the cell, particularly the
complex requirements of hESCs in culture, is
arguable. Such tests may over- or under-estimate
the ability of cells to survive, attach, proliferate
and maintain the undifferentiated state and differentiate into the required cell type. Furthermore, cells that still show membrane integrity at
the time of thawing may die later by apoptosis.
Such tests should not be employed in isolation.
It may be necessary to consider evaluation and
quantification of the viable material at a point
sometime after thawing, such as 24 or 48 h
post-thaw. Consideration should also be given
to use of a range of tests, including appropriate
functional assays, when assessing recovery from
cryopreservation [98].
7.1.2 Choice of cryoprotectant

In choosing an appropriate CPA, consideration
should be given to any known specific effect on
the cells e.g., cytoskeleton effects, membrane
effects, induction of cell differentiation. In order
to provide protection, cells must be equilibrated
in the CPA solution prior to the application of
cooling. CPAs can be toxic to cells and consideration must be given to the intrinsic toxicity of
standard compounds which is time, temperature
and concentration dependent, whether using
a controlled rate freezing method or vitrification [99]. Additives to the solution (e.g., serum)
should be assessed for their ability to mitigate
these and other effects.
Cryoprotectant solutions will exert an osmotic
effect during their addition to and elution from
the cells. If uncontrolled, such effects can be
damaging and compromise cell survival. Osmotic
damage can be reduced or eliminated by the
use of step-wise addition and elution protocols.
Single step protocols (e.g., centrifugation and
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re-suspension in medium containing cryoprotectant) should be assessed for their effect on survival. Step-wise or slow addition or elution protocols should take into account the likelihood of
incurring damage from CPA toxicity.
7.1.3 Choice of primary container

For cell suspensions, the choice of primary container will generally be conditional on the mode
of cryopreservation. The most practical and
generally acceptable options currently available
are straws, vials and bags. Each option should
be assessed for its suitability not only for the
mode of cryopreservation (e.g., whether or not
the required cooling rate is achievable) but also
its ability to prevent or reduce contamination
(primarily during cooling and storage), and its
compliance with regulatory guidelines (such as
requirements for labelling of the primary container). The use of open systems is not considered best practice and represents a hazard to
stored cells (see below).
The primary techniques and methods available
for preservation of hPSC lines are described by
Hunt [100] in Appendix 8. Further expert opinion on preservation technologies can be found in
Day and Stacey [101] and the recently published
informational general chapter ‘Cryopreservation
of Cells available in Pharmacopeial Forum section
39(2)’ [213].
7.1.4 Storage conditions

Scientific evidence suggests that storage at ultralow, sub-zero temperatures (generally accepted
to mean storage in or above liquid nitrogen) does
not result in significant deterioration of material over extended periods of time (measured in
decades, for a review see [102], provided that the
temperature remains stable and uniform. This
may be extended to mechanical refrigeration
at temperatures at or below -160°C. Storage in
mechanical freezers at -80 to -85°C is acceptable
for short periods of time if the sample is to be,
or has been, preserved by freezing, but is likely
to result in potentially damaging ice formation
in vitrified samples. If storage at this temperature is considered necessary, the period of storage
should be validated to show that the cells do not
demonstrate any adverse effects. Storage above
-80°C is not recommended. For vitrified material,
temperatures above, or repeated cycling through,
the glass transition temperature (approximately
-130°C) should be avoided to prevent progressive
formation of ice crystal nuclei.
The most stable conditions for storing cells at
ultra-low temperatures are provided by storage
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under LN2. Consideration should be given to
the potential for cross-contamination of samples
stored in this manner via the liquid. There are
a number of reports in the literature that indicate that contaminants, including viruses, can
survive in LN2 and there is at least one report
of fatal viral transmission through this route. A
formal risk assessment should be carried out of
sample containment (i.e., primary and secondary containers), and alternatives to such conditions considered. Leakage of LN2 into the sample
container also represents an explosive hazard
when samples are removed from storage.
Storage in the gas phase above liquid nitrogen
(often referred to as vapour-phase storage) has
been recommended. Such storage, while reducing the risk of cross-contamination, increases the
likelihood for temperature instability from the
inherent temperature gradient between bottom
and top of the LN2 refrigerator. This temperature gradient may be reduced or eliminated by
modification to, or purchase of, tanks designed
to reduce this temperature gradient. Storage
refrigerators are available that exclude LN2 from
the storage compartment altogether (referred to
as isothermal vessels) or restricted it to areas
below the sample containers, for example by the
use of vapour-phase platforms. Temperature gradients are reduced or eliminated either through
jacketing the vessel with LN2 (the isothermal
approach) or through the use of a heat-shunt
device within the tank or through design of lowloss access to the vessel.
7.1.5 Recovery of frozen or vitrified
materials

Cells can be damaged through inappropriate
thawing and CPA elution protocols. In general,
rapid warming (at 37–40°C) is considered more
effective in preventing cell damage from intracellular ice formation or solution effects of the
CPA during rewarming. Rapid warming is especially important for vitrified material; however,
care must be taken to prevent thermal runaway
and exposure of the thawed material to elevated
temperatures where the temperature-dependent
toxic effects of the CPA may damage the cells. In
designing or applying a cryopreservation protocol
consideration should be given to the method of
rewarming and the freezing/vitrification protocol
optimized to that particular rewarming procedure.
Consideration should also be given to the
method of eluting the CPA to prevent osmotic
damage. The use of non-permeating compounds
such as sucrose or mannitol to prevent excessive
swelling may be considered. Recipients should
future science group
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be provided with validated thawing and elution
protocols and a mechanism for adverse event/
adverse incident reporting.

7.2 Shipment
In Europe there is specific legislation for the
import and export of tissues [88], which also has
technical annexes which prescribe aspects of cell
and tissue procurement, processing, storage and
testing. However, the situation is highly variable around the world. In some countries such
as Israel, a simple statement of commercial worth
is required, whereas in Taiwan there are specific
import and export regulations, and in some
countries such as Singapore, these issues are still
under consideration (to the best of the authors’
knowledge at the time of publication).
Competent couriers are critical to efficient
shipment, and it is best that repositories take
responsibility for using couriers that have good
knowledge of local requirements for import. It is
also important for stem cell repositories to have
service level agreements with couriers that identify standards of service and emergency procedures where cryogens become depleted.
Cells cryopreserved by slow cooling may be
transported in dry ice. Vitrified material should
not be transported in dry ice (solid CO2) at
-79°C, to avoid de-vitrification and cell damage. Cells cryopreserved by either method may
be transported in LN2 dry-shippers which are
probably the most secure form for transport.
Repositories should identify transportation companies with the required technical expertise to
undertake such shipments. Where this is likely to
involve shipments outside of the country of origin,
repositories should be familiar with the regulatory
requirements pertaining to the safe shipment of
cells in dry shippers. Use of air freight couriers
that avoid transportation on commercial passenger airlines may reduce problems associated with
a lack of knowledge of shipping in dry shippers
or dry ice shippers. Where cells are transported
in the absence of temperature data-loggers, consideration should be given to the use of chemical or other indicators to provide information on
temperature during transportation.

8. Future applications of human
pluripotent stem cell lines

8.1 Evaluation of human stem cell
lines for production of biological
medicines
Apart from cell therapy, stem cells or cell lines
derived from stem cells can be envisaged for use
as substrates for the production of biological
www.futuremedicine.com
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medical products such as recombinant proteins
(e.g., growth factors or monoclonal antibodies),
vaccines and conditioned media. A ISCBI subgroup including representatives from the pharmaceutical industry, reviewed the requirements
for cells used to manufacture such products and
provided the following summary.
Guidelines for the testing of diploid cells,
continuous cell lines and stem cells for cell
seed, MCB, WCB and end of production cells
have been provided by Part B of the document,
“WHO Recommendations for the evaluation of
animal cell cultures as substrates for the manufacture of biological medicinal products” [3]. In
cases where a stem cell line has a finite lifespan
(senescence) and a diploid profile, the ISCBI
manufacturing sub-group recommended assessment of the basic characteristics of a stem cell
line by following the criteria of other accepted
diploid cell lines such as MRC-5 for biologics
production. In the case of a stem cell line with a
continuous cell line profile (unlimited capacity
for population doubling), the group considered
that the stem cell line can be included in the
continuous cell line classification. As stated
by WHO, this proposal can be applied to any
animal stem cell lines including human stem
cell lines.
Depending on the product that is made, the
sub-group also proposed reference to the guidelines described in Table 4 .
In addition, specific recommendations for the
testing of each product type should be tailored

to the origin and the derivation process of the
stem cell line and to the functions of the product on a case by case basis. The risks related to
contaminants from the stem cell line have to be
considered in the testing of each product, that
is, viruses, retroviruses and other transmissible
agents, cellular DNA, cellular proteins (growthpromoting proteins).

8.2 Preparation of pluripotent stem
cell lines for use in toxicology assays
The capability of human stem cell lines to create
tissue-like cultures in vitro, could provide valuable information on the toxicity of medicines
and hopefully avoid some of the serious chronic
toxic effects of drugs which were not detected by
standard assays [103,104]. The principles of GCCP
[63] are directly relevant to the use of the undifferentiated hPSC lines used in the development
of toxicology assays. As part of the EC funded
multi-consortium cluster SEURAT-1 [214] consideration has also been given to the kinds of
specific quality control measures needed for
hPSC lines and their development [105]. A diverse
range of differentiation protocols are being used
to develop these assays and the establishment of
assay control parameters, and possibly reference
preparations of toxicants to provide quality control of the differentiated cultures. This will be
vital to ensure reproducibility in assay data and
will be paramount for the successful utilization
of stem cell-based models in toxicology and drug
discovery.

Table 4. Documents providing guidelines for manufacture of biologics from stem cells.
Guidelines

Vaccines

Recombinant Conditioned
proteins
media

WHO/ DRAFT/ 4 May 2010: Recommendations for the evaluation of animal cell
cultures as substrates for the manufacture of biological medicinal products and for
the characterization of cell banks (proposed replacement of TRS 878, Annex 1). See
reference WHO 2010a
International Conference on Harmonization, Q5D, Derivation and Characterization
of Cell Substrates Used for Production of Biotechnological/Biological Products, 1997.
www.ich.org/LOB/media/MEDIA429.pdf
International Conference on Harmonization, Q5A, Viral Safety Evaluation of
Biotechnology Products Derived from Cell Lines of Human or Animal Origin. www.ich.
org/LOB/media/MEDIA425.pdf
International Conference on Harmonization, Q5B, Quality of Biotechnological
Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA
Derived Protein Products. www.ich.org/LOB/media/MEDIA426.pdf
CBER Guidance for Industry, Characterization and Qualification of Cell Substrates
and Other Biological Starting Materials Used in the Production of Viral Vaccines
for the Prevention of Infectious Diseases, 2010. www.fda.gov/downloads/
BiologicsBloodVaccines/GuidanceComplianceRegulation

√

√

√

√

√ (a)

√

√ (b)

√

√

√

(a) Applies to recombinant subunit vaccines. Inactivated vaccines, all live vaccines containing self-replicating agents, and genetically engineered live vectors are
excluded from the scope of this document.
(b) Applies to subunit vaccines only.
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Appendices
Appendix 1
Appendix 1 (a). Compliance and provenance determination.
(1) Embryo provenance determination

Code

Considerations

 (a) Independent review and oversight

 B

 (b) Voluntary informed consent

 B

 (c) Gratuitous donation

 B

 The protocol for obtaining gametes and embryos from living donors
should be subject to independent review. Review and approval of the
hESC derivation protocol may be required in some jurisdictions, but is not
an essential requirement
 hESC-specific consent requirements may exist or subsequent users of hESC
lines may be required to obtain lines for which comprehensive consent
has been obtained. Bank should seek to obtain documentation of consent
protocol
 Banks should receive assurance that donors were not paid for embryos or
storage costs

(2) Compliance determination

Code

Considerations

 (a1) Embryo was donated in a jurisdiction with
no explicit prohibition on hESC derivation
 (a2) Derivation protocol confirms to any unique
legal requirements in jurisdiction where hESC
derived
 (b) Any line derived using IVF for research
purposes, parthenogenesis or SCNT is
identified
 (c) Consent requirement for third-party gamete
donors

 B

 Accepting embryos from jurisdictions where hESC research is restricted
may incur legal liability
 Jurisdiction may have unique requirements in addition to international
standards for research ethics (e.g., embryo research oversight or licensing);
Consistent with 1a
 The use of hESC lines derived from embryos created for research purposes
are prohibited by some jurisdictions and funding bodies

 B

 B

 A

 (c1) hESC lines derived from embryos intended  A
for reproductive use where a third-party
donor(s) was contracted to provide gametes
 (c2) hESC lines derived from embryos for which  A
gamete donor(s) participated in egg sharing or
exchange programs are identified
 (c3) hESC lines derived from embryos created
with anonymous gamete donation are
identified

 A

 (d) Donor medical history

 A/PU

 Some donated embryos may have been created using gametes from
someone other than the embryo donor; Some jurisdictions require consent
from third-party donors
 Bank or entity performing hESC derivation should review donor/recipient
contract for any conditions that would restrict research use
 Policies regarding the use of such embryos or resulting hESC lines are
variable. Bank should review egg-sharing contract or exchange policies
 Certain end-users may not be able to utilize lines derived from embryos
for which gamete donors were paid or where egg sharing, exchange or
anonymous donation has taken place. Documentation serves to enable
end user to perform use eligibility determination

 Requirement for medical history may vary depending on relationship
between donor and recipient of embryo for IVF. If embryos are created
specifically for research, gamete donor medical history should be obtained

Code Key:
A

Advisable (recommended?): Level of attainment recommended at this time by the International Stem Cell Banking Initiative.

B

Baseline: Minimum level of attainment generally consistent with the current standard of care for clinical grade stem cell lines.

NR

Not recommended: This option not recommended at this time. Consideration subject to revision based on new information.

PU

Potentially utility if available but not required: In certain circumstances supplemental information: medical records, biological specimens (e.g., blood or urine
specimens) or quality control assays may be available or have been performed. Banks are encouraged to retain access to supplemental information. Absent
evidence of utility – safety or clinical efficacy – the acquisition of supplemental information should not be required for the development of clinical grade
stem cell lines.

hESC: Human embryonic stem cell; SCNT: Somatic cell nuclear transfer.
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Appendix 1 (b). Informed consent and donor disclosures: compliance determination check list.
2.1 Did the informed consent process communicate the following elements?

Yes

No

N/A

That the somatic tissue/cells would be used for the purpose of stem cell research, including the derivation of stem
cell line(s).
That genetic tests may be performed, including whole-genome sequencing.
That research may be conducted on human transplantation.
That the research is not intended to provide direct benefit to the donor(s) except in the case of autologous
donation.
That the cell lines might be used in research involving genetic manipulation of the cells.
That the cell lines might be used in research involving the mixing of human and nonhuman cells in animal models.
That the research entails both foreseeable risks and benefits.
That any stem cell lines created may be used and stored indefinitely.
That any stem cell lines created may be used in future unspecified research projects.
That the decision whether to donate would not affect future medical care.
That confidentiality will be maintained.
That the cells would be coded or anonymized (i.e. irreversibly de-linked).
That donor recontact may be possible (unless anonymized).
That the donor was informed concerning the disclosure (or not) of general, individuals and/or incidental findings.
That the donor was informed of the right of withdrawal provided this is not overridden by complete anonymization.
That the stem cell lines derived will be deposited in a repository for long-term storage and use.
That once the cells have been used in research, the donor will have no further control over any use of the cells or
derived stem cell lines.
That the cells may be distributed to researchers and institutions within and beyond Canada.
That the cell lines may be used for commercial purposes but without financial benefit to the donor.
That the donor was informed of the researchers’ actual or potential conflicts of interests.
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Appendix 2. Material transfer agreements

A material transfer agreement (MTA) is a contract that governs the transfer of tangible research materials between two organizations
(the provider, who is the owner/custodian or the authorized licensee of the material and associated data, and the recipient), thereby
defining the contractual rights and obligations with respect to the materials and any derivates.
Important issues to consider when drafting or evaluating an MTA include:

Ownership of the materials.

Definition and legal status of original/biological materials, modifications of materials and derivates, progeny;

Definition of commercial purposes, non-profit organizations, investigator or researcher

Intellectual property rights;

Publication rights;

Royalty fees

Confidentiality;

Scope of use and restrictions (e.g., non-commercial/academic vs. commercial research; ethical limitations on types of research to
be conducted (e.g., limitations on research aimed at the generation of gametes);

Use of materials in sponsored research (e.g., industry vs. industry/academic sponsored research);

Transferability of cell line , cell products or data derived from cell products (e.g., genetic sequencing data);

Conflicts with existing agreements;

Compliance with laws and ethical guidelines;

Processing, cost-recovery and other fees

Warranties;

Liability;

Indemnification.
Model material transfer agreements.
UK Stem Cell Bank

USA National Institutes of
Health (NIH), Center for
Regenerative Medicine (CRM)

International Society for Stem
Cell Research (ISSCR)

Clinical/Commercial use http://www.ukstemcellbank.org.uk/cell_lines/eutcd_grade_stem_cell_lines/
depositing_eutcd_stem_cell.aspx
Research Use
http://www.ukstemcellbank.org.uk/legal_agreements.aspx
Master Agreement Regarding Use of the Uniform Biological Material Transfer Agreement
http://www.crm.nih.gov/researchTools/uniform_transfer_agreement.asp
CRM Induced Pluripotent Stem (iPS) Cell Material Transfer Agreement
http://www.crm.nih.gov/researchTools/material_transfer_agreement.asp
Public Health Service Biological Materials License Agreement
http://www.crm.nih.gov/researchTools/bio_mats_agreement.asp
ISSCR Sample Material Transfer Agreement
http://www.isscr.org/home/publications/guide-clintrans/sample-material-transfer-agreement

ATCC

General MTA
http://www.atcc.org/Documents/Product%20Use%20Policy/Material%20Transfer%20Agreement.aspx
Research Use
http://www.atcc.org/en/Documents/Product_Use_Policy/Research_Use.aspx
Commercial Use
http://www.atcc.org/en/Documents/Product_Use_Policy/Commercial_Use.aspx
California Institute for
http://www.cirm.ca.gov/our-funding/stem-cell-regulations-governing-cirm-grants
Regenerative Medicine (CIRM) BioTimes hESC Lines
http://www.cirm.ca.gov/our-funding/biotime-stem-cell-lines-agreement
WiCell
iPS Wisconsin MTA
http://www.wicell.org/media/WiCellAgreements/WiCell-iPS-MTA.pdf
UCSF MTA
http://www.wicell.org/media/WiCellAgreements/WiCell-UCSF-Material-Agreement.pdf
Wisconsin Alumni Research
Agreements
Foundation (WARF)
http://www.warf.org/home/for-industry/Agreements/agreements.cmsx
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Appendix 3. Compliance determination: specific issues to consider for hESCs
Prior to initiation of hESC derivation protocol or intent to bank a hESC line, the following compliance issues should be considered
(see Appendix 1 to 3).
Appendix 3. Compliance determination: specific issues to consider for hESCs.
Embryo donation/
hESC derivation

Some jurisdictions explicitly prohibit the derivation of hESC from human embryos. It is not uncommon for
individuals residing in prohibitive jurisdictions to inquire about research donation to outside research centers or
banks. Embryos originating from prohibitive jurisdiction should not be used for the derivation of hESC lines if an
explicit prohibition is/was effective at the time of donation.
IVF for research
Some national, sub-national jurisdictions or funding organizations impose limits on hESC line eligibility. For
purposes &
example, certain jurisdictions have adopted explicit policies determining which hESC lines may be used in research,
parthenogenesis
including requiring that such lines only be derived from embryos that were created using in vitro fertilization for
reproductive purposes and were no longer needed for this purpose. This reproductive use requirement prevents the
use of IVF to develop hESC lines specifically for clinical application or the use of parthenogenetic lines.
Consequently, lines derived from oocytes (parthinodes) or embryos created for non-reproductive use should be
identified as such.
Special
Most established hESC lines have been derived from embryos that were created using in vitro fertilization for
considerations for
reproductive purposes and were no longer needed for this purpose. Gametes used in the creation of reproductive
third-party gametes embryos frequently come from intimate partners. There are, however, a proportion of embryos created with
gametes from third-party donors. The conditions surrounding the procurement of third-party gametes may
influence the compliance determination and should be documented to the extent feasible. Potential factors to
consider include the following:
• Paid gamete donation: oocyte and sperm donors are routinely financially compensated. Some policies limit the
use of hESC lines derived from embryos for which gamete donors were paid [4] . Banks should be aware of any
payment or financial compensation restrictions in their jurisdiction. In addition, it should be noted that certain
funding organizations have restrictions on the use of hESC lines derived from embryos where gamete donors
were financially compensate beyond the reimbursement of expenses.
• Use restrictions: it is also advisable to review the donor contract to support provenance determination and ensure
there is no clause in the contract that the resulting embryos be used exclusively by the couple to which they were
donated or otherwise restricting research use.
• Oocyte sharing/exchange programs: various mechanisms exist for the financing of fertility treatment. One
mechanism is ‘egg sharing’ where fertility treatment costs are reduced for the donor who consents to donating a
portion of her oocytes to other women seeking treatment for infertility. Jurisdictional variations exist in the
interpretation of this kind of arrangement as a financial incentive, compensation or payment.
It is important to note that the applicability of the above factors relating to third-party gametes will vary by
national, local or supra-national jurisdictions. For instance, all embryos created using in vitro fertilization for
reproductive purposes and no longer needed for this purpose are potentially eligible in some jurisdictions regardless
of third-party donor payment or exchange. However, in other jurisdictions hESC lines derived from embryos for
which a gamete donor(s) were paid are not eligible for research or funding. Documentation of the factors above by
the banking entity will enable end users to determine if specific lines are eligible for use in their jurisdiction, but
such documentation should not be viewed as essential prerequisite for banking.
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Appendix 4. Donor screening protocols for assisted reproductive treatments
The majority of existing hESC lines have been derived from embryos intended for assisted reproductive treatments (ART). Cells
differentiated from hESC lines have been utilized in clinical trials after extensive safety evaluation by national regulatory bodies.
These evaluations incorporate the donors’ medical history and tests that are required in the context of ART treatments for screening
low-risk donors of gametes. Consequently, there is no evidence at this time to support the need for further screening of donors of
embryos used to derive clinical grade hESC lines [8].
Screening assays occurring prior to hESC derivation should be documented. It is sufficient to verify testing was performed in
accordance with prescribed regulatory requirements. For instance, gamete donation (from non-intimate partners) is generally regulated as a biological product and, therefore, subject to both donor infectious disease testing and sample screening (21 CFR part 1271,
subpart C, Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the
donation, procurement and testing of human tissues and cells ). Verifying tests performed (as opposed obtaining quantitative results)
is sufficient. Testing and screening regulations have evolved over time, so the bank should seek to document the specific screening
requirements in place at time of gamete donation.
ART embryos created with anonymous gametes donors should be acceptable for clinical use provided that first, the donor contract
is sufficient to support provenance determination (see section 1 Governance and Ethics); and second, gametes and/or gamete donor
were subject to any required screening and testing for relevant communicable disease agents and diseases (see section 4).
Appendix 4. hESC lines: additional donor screening and medical records.
Third-party (allogeneic)
donation from ART

In the case of gamete donation for the purpose of embryo creation, medical history requirements may
vary depending on the relationship between the donors and the individuals undergoing ART treatment as
well as jurisdictional policy. A third-party gamete donor would typically undergo medical screening and a
medical history will be obtained. Entities deriving hESC lines have demonstrated the ability to obtain
third-party medical history information (www.cirm.ca.gov/CIRMCellLines). Researchers deriving new
hESC lines should inquire about the availability of medical history information. Due to privacy and
contractual considerations it is generally not possible to re-contact third-party donors. Again, it should be
noted that donor-screening requirements have evolved over time, so it is critical to document the time
when gamete donation occurred.
Self (autologous) donation
Embryos created from the gametes of sexually intimate partners for self-reproductive use are not
from ART
necessarily subject to the same screening requirements as third-party (allogeneic) donation. Resulting ART
embryos are generally regulated in a manner consistent with requirements for autologous human
transplantation. In this case, the individual(s) donating the embryo(s) for hESC derivation are the gamete
donors. A medical history is generally performed in the context of ART treatment and may be available. A
medical screening and history may also be obtained at time of embryo donation with donor consent.
There is evidence from hESC derivation protocols that donors may consent to (1) being re-contacted in
the future or (2) allow linkage to their medical records [8] . Consequently, entities deriving or banking
clinical grade lines should examine the possibility of donor re-contact and record linkage options when
possible.
Gamete donation for research Blastocysts may also be made specifically for research using assisted reproductive technologies. In this
purposes
case, it is recommended to obtain a medical history at the time of gamete donation to inform risk
assessment. When available, banks should associate anonymous medical history with the banked hESC
lines. Banks may also seek to determine whether the donor(s) of gametes used to derive the hESC line
underwent a previous medical screening or history consistent with requirements for tissue intended for
allogeneic human transplantation. The nature and extent of such screening should be documented.
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Appendix 5. Donor selection, eligibility, release criteria and screening procedures: normative and
institutional documents
Appendix 5.
CANADA

FRANCE

UNITED STATES

SINGAPORE
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Standard Z.900.1 “Cells, Tissues and Organs for Transplantation: General requirements”. Canadian Standards
Association. (2nd edition under review)
Safety of Human Cells, Tissues and Organs for Transplantation Regulations (SOR/2007–118) (Enabling Statute is
the Food and Drug Act)
http://www.laws.justice.gc.ca/en/SOR-2007–118/FullText.html
Guidance Document for Cell, Tissue and Organ Establishments (Safety of Human Cells, Tissues and Organs for
Transplantation- April 6th, 2009)
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/brgtherap/cell/cto_gd_ld-eng.pdf
Transplantation Registration Application Form
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/compli-conform/frm_0171-eng.pdf
Annex E (normative) Exclusionary Criteria for Risk Factors Associated with HIV, HBV, and HCV
http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/brgtherap/cto-reg-annexe-eng.pdf
Regulations Amending the Food and Drug Regulations (1024—Clinical Trials)
(Division 5: Drugs for Clinical Trials Involving Human Subjects)
http://www.hc-sc.gc.ca/dhp-mps/compli-conform/clini-pract-prat/reg/1024-eng.php
Canadian Institute for Health Research Updated Guidelines for Human Pluripotent Stem Cell Research 2010.
Bioethics Law (2004)
Arrêté du 21 décembre 2005 pris en application des articles R. 1211–14, R. 1211–15, R. 1211–16 et R. 1211–21
du code de la santé publique
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000456466&dateTexte=
Décret n° 2005–1618 du 21 décembre 2005 relatif aux règles de sécurité sanitaire portant sur le prélèvement
et l’utilisation des éléments et produits du corps humain et modifiant le code de la santé publique (partie
réglementaire)
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000636261&dateTexte=
Arrêté du 11 avril 2008 relatif aux règles de bonnes pratiques cliniques et biologiques d’assistance médicale à
la procréation
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000018829426&dateTexte=
Décret n° 2008–588 du 19 juin 2008 transposant en matière de don de gamètes et d’assistance médicale à la
procréation la directive 2004/23/CE du Parlement européen et du Conseil du 31 mars 2004
http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000019060568&dateTexte=
Guidance for Industry. Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and TissueBased Products (HCT/Ps)
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/
Guidances/Tissue/ucm091345.pdf
International Compilation of Human Research Standards (2012)
http://www.hhs.gov/ohrp/international/intlcompilation/intlcompilation.html
Guidelines for Healthcare Institutions Providing Tissue Banking: Regulation 4 of the Private Hospitals and
Medical Clinics Regulation
http://www.moh.gov.sg/mohcorp/uploadedFiles/Publications/Guidelines/institutions_providing_tissue_
banking_guidelines.pdf
Medicines Act (Chapter 176, ss. 18 and 74) Medicines (Clinical Trials) Regulations
http://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/legislation/medicines_
act.Par.41439.File.dat/MEDICINES%20(CLINICAL%20TRIALS)%20REGULATIONS.pdf
Medical (Therapy, Education and Research) Act
http://statutes.agc.gov.sg/non_version/cgi-bin/cgi_retrieve.pl?actno=REVED-175&doctitle=MEDICAL%20
%28THERAPY%2c%20EDUCATION%20AND%20RESEARCH%29%20ACT%0a&date=latest&method=part
Human Organ Transplant Act
http://statutes.agc.gov.sg/non_version/cgi-bin/cgi_retrieve.pl?actno=REVED-131A&doctitle=HUMAN%20
ORGAN%20TRANSPLANT%20ACT%0a&date=latest&method=part&sl=1
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Real Decreto 1301/2006 (10 Noviembre, 2006) por el que se establecen las normas de calidad y seguridad para
la donación, la obtención, la evaluación, el procesamiento, la preservación, el almacenamiento y la distribución
de células y tejidos humanos y se aprueban las normas de coordinación y funcionamiento para su uso en
humanos.
Ley 14/2006 (26 Mayo, 2006) sobre técnicas de reproducción humana asistida.
Real Decreto 65/2006 (30 Mayo, 2006) por el que se establecen requisitos para la importación y exportación
de muestras biológicas.
Plan Nacional de Sangre de Cordón Umbilical.
http://www.ont.es/infesp/DocumentosDeConsenso/plannscu.pdf
Programa de Garantía de Calidad en el proceso de donación. Organización Nacional de Transplantes.
http://www.ont.es/infesp/Paginas/ProgramadeGarantiadeCalidad.aspx
Real Decreto 2132/2004 begin_of_the_skype_highlightingend_of_the_skype_highlighting, de 29 de octubre,
por el que se establecen los requisitos y procedimientos para solicitar el desarrollo de proyectos de
investigación con células troncales obtenidas de preembriones sobrantes (BOE 30 octubre).
Ley 14/2007, de 3 de julio, de Investigación biomédica.
ORDEN SCO/393/2006, de 8 de febrero, por la que se establece la organización y funcionamiento del Banco
Nacional de Líneas Celulares.
Banco Nacional de Líneas Celulares requisitos para depósito y acceso
http://www.isciii.es/htdocs/terapia/terapia_bancocelular.jsp
Requisitos que debe cumplir la Hoja de Información a los Participantes y el Consentimiento Informado para
investigaciones que impliquen la generación de células pluripotentes inducidas (iPS)
http://www.isciii.es/htdocs/terapia/terapia_comiteetica.jsp
Real Decreto 1527/2010 (noviembre, 2010) por el que se regulan la Comisión de Garantías para la Donación y
Utilización de Células y Tejidos Humanos y el Registro de Proyectos de Investigación
http://www.boe.es/boe/dias/2010/12/04/pdfs/BOE-A-2010–18654.pdf
Guidelines for Stem Cell Research and Therapy. Department of Biotechnology and Indian Council for Medical
Research (2013)
The Assisted Reproductive Technologies (Draft Regulation), Rules – 2010. Ministry of Health and Family
Welfare, Government of India.
The Assisted Reproductive Technologies (Draft) Bill. Ministry of Health and Family Welfare, Government of
India
Therapeutic Goods (Charges) Amendment Act 2010 (No. 53, 2010). An Act to amend the Therapeutic Goods
(Charges) Act 1989, and for related purposes.
Australian code of good manufacturing practice for human blood and blood components, human tissues and
human cellular therapy products (2013)
National Statement on Ethical Conduct in Human Research (2007), developed jointly by National Health and
Medical Research Council, Australian Research Council and Australia Vice-Chancellors’ Committee
Ethical Guidelines on the use of assisted reproductive technology in clinical practice and research (June, 2007),
National Health and Medical Research Council.
NHMRC Embryo Research Licensing Committee, Information Kit, National Health and Medical Research Council
(2008).
UKSC Bank, MRC, Code of Practice for the use of Human Stem Cell Lines (April, 2010)
HFEA Code of Practice (8th edition), HFEA (2009)
The Human Fertilisation and Embryology Act (2008)
UK Stem Cell Tool Kit http://www.sc-toolkit.ac.uk/home.cfm
Data and Tissues Tool Kit http://www.dt-toolkit.ac.uk/home.cfm
HTA Code of Practice on Research (2009)
Human Tissue Act (2004)
Human Tissue (Quality and Safety for Human Application) Regulations 2007
British Standards Institute (BSI) Publicly Available Specification PAS 83:2012 Developing human cells for clinical
applications in the European Union and the United States of America. Guide
BSI Publicly Available Specification PAS 84:2012 Cell therapy and regenerative medicine. Glossary
BSI Publicly Available Specification PAS 93:2011. Characterization of human cells for clinical applications. Guide
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SWEDEN

SWITZERLAND

JAPAN

Tissue Law: Lag (2008:286) om kvalitets- och säkerhetsnormer vid hantering av mänskliga vävnader och celler,
som reglerar hanteringen av vävnader och celler som ska användas för transplantation, assisterad befruktning
och tillverkning av läkemedel.
Lagens bestämmelser konkretiseras ytterligare i de föreskrifter som tagits fram av Socialstyrelsen respektive
Läkemedelsverket.ocialstyrelsens föreskrifterom donation och tillvaratagande av vävnaderoch celler; beslutade
den 18 november 2008.
Federal Act of 19 December 2003 on Research Involving Embryonic Stem Cells (Stem Cell Research Act, StRA)
(RS 810.3, Loi relative à la Recherche sur les Cellules Souches (LRCS)), http://www.admin.ch/ch/e/rs/c810_31.
html
Federal Act of 18 December 1998 on Medically Assisted Reproduction (Reproductive Medicine Act, RMA) (RS
810.1 Loi fédérale du 18 décembre 1998 sur la procréation médicalement assistée (LPMA) www.admin.ch/ch/f/
rs/c810_11.html
Federal Act of 8 October 2004 on the Transplantation of Organs, Tissues and Cells (Transplantation Act)
The Federal Act on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA) , in force since 1st
January 2002 (www.admin.ch/ch/e/rs/c810_21.html)
Federal Office of Public Health (www.bag.admin.ch/index.html?lang=en)
Swissmedic (Swiss agency for the authorisation and supervision of therapeutic products): the responsible
regulatory authority on behalf of the Federal Office of Public Health (www.swissmedic.ch/index.html?lang=en)
The Act of Pharmaceuticals and Medical Devices
MHLW: Ministry of Health, Labor and Welfare (25/11/2014)
Revision of former Pharmaceutical Affairs Act.
Producing regenerative and cellular therapeutic products in firms
The Act on Safety of Regenerative Medicine
MHLW (25/11/2014)
Providing regenerative medicines within hospitals and clinics.
The previous guidelines ”The Guideline on clinical research using human stem cells” and “Ethical Guidelines for
Clinical Research” were abolished.
Guidelines on Ensuring Quality and Safety of Products Derived from Processed Human Cell/Tissue
Autologous: MHLW Notification No.0208003 (8/2/2008)
Allogeneic: MHLW Notification No.0912006 (12/9/2008)
Guidelines on Ensuring the Quality and Safety of Products Derived from Processed Human Stem cells
Autologous Somatic Stem Cells: MHLW Notification No.0907–2 (7/9/2012)
Allogenic Somatic Stem Cells: MHLW Notification No.0907–3 (7/9/2012)
Autologous iPS(-Like) Cells: MHLW Notification No.0907–4 (7/9/2012)
Allogenic iPS(-Like) Cells: MHLW Notification No.0907–5 (7/9/2012)
Embryonic Stem Cells: MHLW Notification No.0907–6 (7/9/2012)

THAILAND
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Guidelines on the Derivation of Human Embryonic Stem Cells
Guidelines on the Distribution and use of Human Embryonic Stem Cells
MEXT : Ministry of Education, Culture, Sports, Science & Technology (25/11/2014)
Revision of regulations for clinical use of hES cells
Thai Medical Council Regulation (November, 2009)
Thai Food and Drug Administration Regulation (March, 2009)
Medica
l Council’s Medical Practice Act BE2525 (AD 1982)
Division of Medical Registration of the Department of Health Service Support’s Sanatorium Act BE 2525 (AD
1982)
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NCI – NIH-USA
ISSCR
OECD
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Bioethics and Safety Act (Jun, 2008) http://www.moleg.go.kr/FileDownload.mo?flSeq=25769 (Article 15)
Enforcement Decree of Bioethics and Safety Act (Nov, 2009) http://www.moleg.go.kr/FileDownload.
mo?flSeq=31613
Enforcement Rule of Bioethics and Safety Act (Dec, 2009) http://www.moleg.go.kr/FileDownload.
mo?flSeq=31607
Pharmaceutical Affairs Act (Apr, 2007)
Enforcement Decree of Pharmaceutical Affairs Act (Jun, 2007)
A draft of “Regulation of Review and Authorization of Biological Products”(Jul, 2009)
law on human tissues (19th March 2010), Ministry of Human Welfare (MHW)
Enforcement regulations (Oct 2004), MHW
Guidelines for Management of cord blood bank (Act 2005), FDA.
Regulation of Organ Banks
Regulation of Human Biobanks
The regulation of prevention of infectious diseases
Guidelines of research usage of human biopsy, tissue and fluid
Guidelines of research ethics for human embryo and embryonic stem cells.

人体器官移植条例Regulations on human organs transplantation (4–6–2007)
http://wsj.sh.gov.cn/website/b/28586.shtml
骨组织库管理Standard for human musculoskeletal tissue bank( 3–1–2011)
眼库管理Standard for human eye tissue bank( 3–1–2011)
http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohzcfgs/s7850/201009/48944.htm
脐带血造血干细胞治疗技术管理规范Regulations on therapeutic technology of cord blood stem cells (11–13–
2009)
http://wsj.sh.gov.cn/website/b/48446.shtml
医疗技术临床应用管理办法Regulations on therapeutic technology for clinics (3–2–2009)
http://wsj.sh.gov.cn/website/b/43522.shtml
涉及人的生物医学研究伦理审查办法Ethical Guidelines on the use of human tissue in research (1–11–2007)
http://wsj.sh.gov.cn/website/b/28676.shtml
Commission Directive 2006/86/EC implementing Directive 2004/23/EC of the European Parliament
and of the Council as regards traceability requirements, notification of serious adverse reactions and
events and certain technical requirements for the coding, processing, preservation, storage and
distribution of human tissues and cells. (October, 2006)
Commission Directive 2006/17/EC
implementing Directive 2004/23/EC of the European Parliament and of the Council as regards
certain technical requirements for the donation, procurement and testing of human tissues and
cells. (February, 2006)
Directive 2004/23/EC
of the European Parliament and of the Council of 31 March 2004 on setting standards of quality
and safety for the donation, procurement, testing, processing, preservation, storage and
distribution of human tissues and cells. (April, 2004)
European Parliament legislative resolution
on the Council common position adopting a European Parliament and Council directive on setting
standards of quality and safety for the donation, procurement, testing, processing, preservation,
storage and distribution of human tissues and cells (10133/3/2003 - C5–0416/2003 2002/0128(COD)) (December, 2003)
Best Practice for Repositories: Collection, Storage, Retrieval and Distribution of Biological Materials
for Research (2012)
Cellular Therapy Accreditation Manual (5th Edition, 2012)
Position Paper: Towards Global Standard for Donation, Collection, Testing, Processing, Storage and
Distribution of Allogeneic HSC and Related Cellular Therapies (2008)
Guidance of Good Cell Culture Practice – A Report of the Second ECVAM Task Force on Good Cell
Culture Practice (2005)
NCI Best Practice for Biospecimen Resources (2011)
Guidelines for the Clinical Translation of Stem Cells (2008)
Guidelines for the Conduct of Human Embryonic Stem Cell Research (2006)
Guidelines for Human Biobanks and Genetic Research Databases (HBGRDs) (2009)
OECD Best Practice Guidelines for Biological Resource Centers (2007)
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Meets Specification
Meets Specification

Meets Specification

No detectable contamination
No detectable contamination (sensitivity and
specificity to be validated with service provider)
Diploid chromosomes predominant in cells
analysed (for specifications see section 4).
Viability should typically be ≥50% of thawed cells
(N.B. this does not necessarily equate with
functional performance of the culture and is
merely an indicator of the ability to expand cells
from production purposes)
Typically 20 to 40 h

Meets Specification

Meets Specification

Meets Specification

Test results prior to
release

All alleles match parent cell line

Criteria/specification

In vitro and in vivo non-specific and specific (virus screening
should be directed by risk assessment and where there is risk of
blood born virus contamination may include viruses such as HIV
1 and 2, HBV, HCMV, HCV, HHV 6–8, EBV, HTLV I&II, B19 etc.)
Test to assure silencing of reprogramming vectors or elimination
of episomal non-integrating vectors

Viral contamination3*

www.futuremedicine.com

RTPCR/qPCR, antibody based detection

Reprogramming vectors
and or exogenous
expression of
reprogramming factors
not detectable

Typically ≥70% of hPSCs expressing hPSC markers Meets Specification
and ≤10% of hPSCs expressing SSEA-1 (N.B actual
values should be based on local experience with
each cell line)
Criteria should be set by repository depending on Meets Specification
method used, but embryoid bodies and teratomas
should express markers of ectoderm, mesoderm
and endoderm.
No detectable contamination (N.B. levels of
Meets Specification
sensitivity will need to be validated by the
repository or service provider)

*Release criteria should include test sensitivity and test specificity where appropriate.
**Characterization for information, but not release.
***Testing should be performed on at least 1% of vials, but no less than 2 of the Bank from which cells are to be released.
1. Some suitable tests are described in the European Pharmacopoeia methods and 21 CFR 610.30.
2. For further information, refer to the Consensus Guidance for Banking and Supply Of Human Embryonic Stem Cell Lines For Research Purposes (reference ISCBI (2009) in main text) (1)
3. Examples of suitable tests are described in the ICH guidelines Q5A [105].
4. Cell banks should be free of extraneous material apart from that which is unavoidable in the manufacture process. For further information, refer to ICH Q3 on ‘Impurities’ [106]
5. It is important to note that the tests indicated here are examples of tests applied typically to pharmaceutical products, and whilst they may add value by detecting contamination that may not be detected
in a standard phamacopoeial ‘sterility’ test, they may also miss certain bacterial contaminants lacking the cell wall components detected in pyrogencitiy and limulus lysate assays. These tests may also give
false positive results where contamination is not present but bacterial components persist in cell culture reagents. Cell banks should keep a watching brief for alternative qualified tests, which may become
available and give broader capacity for detecting both bacterial and fungal contamination such as PCR for microbial ribosomal RNA.

Reprogramming
factors*

Pluripotency**

Flow cytometry of hPSC markers of self renewal and hPSC state
(these are to be selected and qualified the repository but
possible examples include Oct-4, TRA 1–60, TRA 1–81, SSEA-3,
SSEA-4, Alkaline Phosphatase, Rex-1, SSEA-1 negative)
Tests indicating potential pluripotency (e.g., teratoma
production, embryoid body formation, directed differentiation see section 5.4)

Antigen expression

Characterization and stability (N.B. stability testing will need to be established by each repository, but may include culture to passages or population
doublings to limits anticipated for cell therapy products)**

Growth characteristics* Determine doubling time

Typically Short Tandem Repeat (STR) Testing (other techniques
may be used such as, Human Leukocyte Antigen (HLA) Testing
Bacteria/Fungi (sterility) Inoculation of microbiological media to detect growth of
1*
bacteria and fungi
Mycoplasma1*
Pharmacopeia tests include direct culture, direct stain (DAPI or
Hoechst 33258) and Vero culture followed by direct stain.
Alternative PCR tests are now becoming acceptable
Karyotype2*
Chromosome count of 20 metaphases and G-band analysis of a
further 10 metaphases (see [1] and Section 4)
Viability1*
Viability must be quantified using a validated method. A lower
limit for acceptability should be indicated

Identity*

Test

Development of seed stocks of pluripotent stem cells for clinical applications
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Flow cytometry (of note, markers and acceptable limit may vary with
cell line and local culture procedures)

Cell debris**
Meets Specification

Meets Specification

See section 6.4

Meets Specification

Meets Specification

Test results prior to
release

Acceptable levels will need to be defined and
validated locally (international standards to qualify

Contamination with non-hPSC markers should be
below levels
Maximum levels of cell debris specified based on
local data on each cell line.

Criteria/specification

*Release criteria should include test sensitivity and test specificity where appropriate.
**Characterization for information, but not release.
***Testing should be performed on at least 1% of vials, but no less than 2 of the Bank from which cells are to be released.
1. Some suitable tests are described in the European Pharmacopoeia methods and 21 CFR 610.30.
2. For further information, refer to the Consensus Guidance for Banking and Supply Of Human Embryonic Stem Cell Lines For Research Purposes (reference ISCBI (2009) in main text) (1)
3. Examples of suitable tests are described in the ICH guidelines Q5A [105].
4. Cell banks should be free of extraneous material apart from that which is unavoidable in the manufacture process. For further information, refer to ICH Q3 on ‘Impurities’ [106]
5. It is important to note that the tests indicated here are examples of tests applied typically to pharmaceutical products, and whilst they may add value by detecting contamination that may not be detected in a standard
phamacopoeial ‘sterility’ test, they may also miss certain bacterial contaminants lacking the cell wall components detected in pyrogencitiy and limulus lysate assays. These tests may also give false positive results where
contamination is not present but bacterial components persist in cell culture reagents. Cell banks should keep a watching brief for alternative qualified tests, which may become available and give broader capacity for
detecting both bacterial and fungal contamination such as PCR for microbial ribosomal RNA.

Non-specific tests for
Examples include:
bacterial contamination a) Endotoxin [5]**: limulus amaebocyte lysate (LAL) test
b) Pyrogenicity [5] **:
Rabbit pyrogen test method
c) PCR for microbial rRNA genes:
Vial labelling**
A water-resistant written, printed or graphic indication must be
affixed to each container/ package of hPSCs describing critical
information about the cells/product

Flow cytometry using hPSC and non-hESC markers

Examples of test method(s)

Differentiated cells**

Purity [5]

Test
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Appendix 7. Examples of QA definitions used in GMP manufacture

The terminologies given here are purely examples drawn primarily from the FDA tissue banking regulation [108]. There are no wholly
agreed terminologies for this area and it is therefore important to use the definitions of QA terms recommended in national guidelines. In some cases there are significant difference in the scope of a definition under different jurisdictions such as the definitions
for serious adverse events in the EU and the USA. ICH definitions [109] is very similar to FDA Medwatch and is probably one of the
best harmonized terminologies. The PAS terminology [2] provides the UK and EU definitions and the regulatory reference for QA
terms in Europe is the European Tissues and Cells Directive.
QA DEFINITIONS
ACCEPTANCE CRITERIA: The specifications and acceptance/rejection criteria, such as acceptable quality level and unacceptable quality level, with
an associated sampling plan, that are necessary for making a decision to accept or reject a lot or batch of raw material, intermediate, packaging
material, or product. This term can also be applied to validation.
ADVERSE EVENT: Any untoward medical occurrence in a patient or clinical investigation subject administered with a pharmaceutical product and
that does not necessarily have to have a causal relationship with this treatment.
ADVERSE REACTION: A noxious and unintended response to any human cells, tissues, and cellular and tissue-based products for which there is a
reasonable possibility that the HCT/P caused the response.
ASEPTIC PROCESSING: The processing of cells/product by methods that avoid or minimize contamination with microorganisms from the
environment, processing personnel and/or equipment.
AUDIT: A review of procedures, records, personnel activities, reagents, materials, equipment and facilities to determine adherence to standards and
regulations.
BATCH: A batch, sometimes called lot, is defined as an entity, by either time or quantity or both, of a product that is intended to have a uniform
character and quality. A batch must be produced within predefined and specified conditions following a defined manufacturing process.
BATCH MANUFACTURING RECORD (BMR): The necessary quality documentation for tracing the complete cycle of manufacture of a batch or
lot.
BATCH RECORD REVIEW: The process of reviewing and approving all Product Manufacturing and control records is called the batch record
review. This includes, but is not limited to, packaging and labeling. The batch record review is performed by the quality unit to determine compliance
with all established approved written procedures before a batch is released.
DISPOSITION: The destination of cells/product for research, transplantation or discard.
DISTRIBUTION: A process including the receipt of a request for, selection of, and inspection of cells/product, and their/its shipment for delivery to
recipient.
DOCUMENTATION: Any procedures, instructions, logbooks, records, raw data, manuals, and policies associated with the development,
manufacture, testing, marketing and distribution of a product required demonstrating compliance with applicable worldwide regulatory
requirements.
EQUIPMENT QUALIFICATION: Protocols to evaluate equipment performance following instillation and before use, to ensure normal function
within required tolerance limits.
FACILITIES: The facilities are used for the manufacturing of cell therapy products with predefined environmental control following the applicable
standards of e.g., particulate and microbial contamination. The facilities should be constructed and used reducing the introduction, generation and
retention of contaminants within the area.
IN-PROCESS CONTROL (IPC): Testing and activities performed during production to monitor and, if necessary, adjust the process to assure that
the product conforms to its specifications.
INTERMEDIATE: An intermediate product e.g., cell line that must undergo further processing before it becomes a final product.
LABEL: A written, printed or graphic indication affixed to a container/ package describing critical information about the cells/product.
LOT: Cells/product derived from one donor, banked at one time using the same reagents and materials, and identified by a unique identification
number.
PROCEDURE: A series of ordered steps designed to achieve a specific outcome when followed.
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PROCESS VALIDATION: Establishing documented evidence that provides a high degree of assurance that a specific process will consistently produce
a product meeting its pre-determined specifications and quality attributes.
QUALITY: The term quality is used as the totality of features and characteristics of a product that bears on its ability to satisfy stated or implied
needs including the conformance to requirements to specifications.
QUALITY ASSURANCE: A formal methodology designed to provide adequate confidence that the entire production of a product will fulfil
requirements for quality under a wide conditions of operation. Quality assurance includes formal review of care, problem identification, corrective
actions to remedy any deficiencies and evaluation of actions taken.
QUALITY ASSURANCE UNIT: Sets policies, procedures and specifications, audits, reviews, assesses and training including continuous evaluation of
the adequacy and effectiveness of the overall quality program.
QUALITY CONTROL: A procedure or set of procedures intended to ensure that a manufactured product adheres to a defined set of quality criteria.
QUALITY CONTROL UNIT: The function in the quality unit that is responsible for the ongoing control of product and environment quality.
Therefore the quality control unit (QC) has the overall responsibility for acceptance or rejection of e.g., raw materials, cell lines/intermediate
products/final products, packaging components.
IN-PROCESS CONTROLS (IPC), LABELLING AND INSPECTION: Assurance that supporting systems are being controlled and monitored.
QUALITY SYSTEM: Organizational structure, responsibilities, procedures, processes, and resources for implementing quality management.
QUARANTINE: The storage of materials/cells/ product in an isolated area until deemed safe (cleared/approved) for use.
SERIOUS ADVERSE EVENT/REACTION (ICH DEFINITION: Topic E2A1): Is an untoward medical occurrence which is: fatal, life-threatening
(risk of death at the time of the event), disabling, or incapacitating resulting in hospitalization, or medically significant congenital abnormalities.
SERIOUS ADVERSE EVENT (EU TCD): Any untoward occurrence associated with the procurement, testing, processing, storage and distribution of
tissues and cells that might lead to the transmission of a communicable disease, to death or life-threatening, disabling or incapacitating conditions for
patients or which might result in, or prolong, hospitalization or morbidity
SERIOUS ADVERSE REACTION (EU TCD): Unintended response, including a communicable disease, in the donor or in the recipient associated
with the procurement or human application of tissues and cells that is fatal, life-threatening, disabling, incapacitating or which results in, or prolongs,
hospitalization or morbidity.
SPECIFICATIONS: Used for the predefined written, chemical, physical, biological and environmental characteristics for testing a product or system.
This includes, but is not limited to, starting materials, packaging materials, intermediate, bulk, or product.
STANDARD: An accepted or authoritatively established principle or practice for quality assurance (e.g., SOP).
STANDARD OPERATING PROCEDURE: A detailed description of a procedure or process for quality assurance.
TRACEABILITY: The ability to locate cells/product at any point/step during production, processing, testing, storage, distribution or disposition.
VALIDATION: The procedure for establishing documented evidence that a specific system is constructed and operates according to a predetermined
set of specifications and guidelines. Validation includes but is not limited to: equipment, computer systems, production processes, cleaning
procedures, facilities, utilities as well as analytical methods.
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Appendix 8: Preservation technologies and methods

Mode of cryopreservation
Two approaches to cryopreservation have been applied to stem cells: vitrification and slow cooling [101]. Both of these are capable of
ensuring high survival if appropriately applied.

Vitrification
The vitrification method currently applied is a non-equilibrium approach relying on ultra-rapid cooling with low concentrations of
CPA to achieve the ice-free vitreous state. This is a meta-stable state which is prone to de-vitrification (with the potential for subsequent damaging ice formation) if those conditions necessary to maintain the vitreous state (notably a stable low temperature) are not
maintained (see storage and transportation).
The choice of container and the unit volume of material being cooled should be considered when vitrification methods are
employed, since both these will affect the maximum attainable cooling and warming rate. The ultra-rapid cooling rates necessary
to effect vitrification require both high surface to volume ratios (with regard to container geometry) and small volumes (of the order
of microliters per unit sample). In preparing large banks of cells, consideration should be given to the practicality of this method for
scale-up due to the need to preserve relatively small numbers of cells at one time.
Consideration should also be given to the use of open straws and Dewars containing non-sterile liquid nitrogen (LN2) into which
the straws are plunged. Neither of these can be considered to be best practice both from a microbiological or regulatory perspective.
Alternatives to the open straw method, such as closed straws and straw-in-straw methods, should be considered, but there may also
be important logistical constraints (e.g., size of the bank, mode of transportation) which must be reconciled with the requirements
of the preservation method.
Other alternatives for ice-free preservation, such as equilibrium approaches utilizing high concentrations of CPA [99] and/or the
addition of natural or synthetic ice blocking molecules coupled with slow cooling [110] have not as yet been applied to stem cells.

Conventional slow cooling
During slow cooling, ice formation will occur within the system resulting in the concentration of solutes in the remaining liquid
phase in which the cells reside. Damage results mainly from exposure to these high solute concentrations (so-called solution effects),
but may also occur as a result of intracellular ice formation. Ice formation within cells is generally a consequence of rapid cooling,
but may occur in tissues at slow cooling rates as a random event leading to ice propagation to surrounding cells. It should be noted
that CPAs militate against damaging solution effects of slow cooling but not against damage caused by intracellular ice formation.
Conventional slow cooling methods are generally more amenable to the production of large banks of cells produced as ‘single’ cell
suspensions. For stem cells cryopreserved as colony fragments, if slow cooling methods are to be applied, consideration should be given
to methods to control ice nucleation such as the inclusion of ice nucleating agents or seeding samples at high sub-zero temperature [111].

Methods of cooling
The high cooling rates required for vitrification are generally obtained by direct immersion of the sample into a cryogen, usually
liquid nitrogen. Slow cooling can be effected by either controlled rate cooling or the use of passive cooling devices. In both cases,
consideration must be given to issues of sample contamination and contamination of the cleanroom as well as those of reproducibility and validation (see validation).
Controlled rate freezers (CRFs) in which the chamber containing the product is cooled by the injection of LN2 will generally be
located outside the cleanroom environment unless the resulting nitrogen vapour can be ported to the outside of the cleanroom and
the chamber can be effectively sterilized between cooling cycles. If such devices are used, outside the production area, consideration
should be given to the method by which cells are moved to the CRF, to ensure that CPA exposure time/temperature does not compromise cell survival or lead to contamination.
Liquid nitrogen-free, CRFs, such as those employing the Stirling Cycle principle, may provide an alternative [112,113]. While such
equipment provides a clean room-compatible solution for controlled rate freezing, they should be assessed for their ability to provide
the required cooling rates, unit volumes and bank sizes appropriate to the cell lines being banked.
The end point temperature at which cells are transferred from the CRF to low-temperature storage should be set at a sufficiently
low temperature to ensure that during handling and transfer to permanent storage any rise in temperature of the samples does not
expose the cells to damaging sub-zero temperatures (above approximately -70°C for frozen cells and above the glass transition temperature for vitrified material).
Passive cooling devices are generally placed inside a mechanical freezer to equilibrate. A uniform and reproducible cooling rate can be
obtained if there is careful control of the sub-zero environment. A sub-zero temperature of at least -70°C should be employed in order to
limit the cells exposure to the most damaging sub-zero temperatures (between the equilibrium freezing point and ~ -40 to 60°C) and
assist in providing a relatively linear cooling rate over this temperature range. Consideration should be given to temperature logging of a
control sample for QC purposes, the use of a designated freezer and procedures to control access to this freezer during cryopreservation.
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Appendix 9. Review of teratoma methodologies used in different laboratories
18 laboratories from 16 countries responded to a set of questions (see table) on the teratoma assays they used for evaluation of hESC
lines. Methodologies used for teratoma assays showed little concordance for strain of mouse, site of injection, number of cells/volume,
end point, inspection for metastasis and processing and analysis of tumors (data obtained by S Oh and L Healy of ISCBI).
Method component

Details requested

Range of methods reported

Preparation of hPSCs

Culture method used prior to harvesting

Feeder and feeder-free cultures used (some labs used both
methods).
4 methods used (TrypLE, trypsin, collagenase, mechanical)

Harvest method used
Post-harvest processing before inoculation

Cells inoculated

Number and viability of cells inoculated

Site of inoculation

Anatomical site and means of administration
(e.g. syringe, surgical incision with cells on a
substrate)?
Strain of mouse used

3 methods used (cell centrifuged and resuspended, cells
washed in growth medium or PBS and resuspended in the
same, cells resuspended in medium with MatrigelTM)
Range of methods based on cell number (1000 -10,000,000),
cell viability (range 80–95%), injection volume 20–150ul, and
no determination of cell number or viability.

4 different sites used (legs intramuscular (both sides), Kidney
capsule, intra-testicular, subcutaneously head and neck and
flank)
Test animal
Seven different strains of mouse used (Nude Balb/c, SCID
undefined, Nude/nude, SCID/Beige, SCID c gamma c -/-,
SCID undefined, NOD/SCID, NOD/MrkBomTac-Prkdc SCID).
Frequency and natural onset of spontaneous None identified or ‘low’
tumors in the mouse strain
Age of animals used
2 age ranges used (7–8 weeks (majority) or 5–8 months)
Replicates of test
No. of animals used for each test
Ranged from 1–4 per cell line (3/cell line (majority), 1/cell line
with 2–4 injection sites, 4/cell line)
Observation of animals
Typical number of weeks post inoculation at 4–12 weeks
which mice are sacrificed
Is there a maximum end point for incubation 3 different limits used (2–4 months, tumor growth allowed to
or are mice kept until natural death?
reach 1–1.5 cm or tumor growth allowed to reach 2 g)
Tumor incidence
Frequency of mice developing tumors per
Ranged from none-100% with an equal number of
experiment
participants reporting incidence of tumors in mice at
30–50% and 80–100%.
Method of tumor location
Palpation and observation
Numbers of tumors expected per mouse
1–2 tumors per site
Frequency of metastasis
Majority of participants reported metastases
Tumor preparation
Point at which palpable tumors are recovered 5–12 weeks or maximum size of 0.5–1.5 cm or maximum
weight of 2 g
Processing of tumor
Tumors fixed by alternative methods (paraformaldehyde or
formalin, paraffin, cryosections) depending on post-fixation
testing including 3 different techniques (histology [H&E, PAS
etc], immune-staining or PCR).
Evaluation and reporting of Minimum criteria (in terms of histological
Evidence of 3 germ layers
tumors
data) to establish a cell line is ‘pluripotent’
Are results from more than one mouse used 50% responded ‘no’, 50% responded ‘yes’ if using the same
in combination?
cell line
Variation in results observed between cell
Of those responding 50% reported no variation and 50% did
lines
see a significant variation

44

Regen. Med. (2015) 10(2)s

future science group

